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DECODING PROSTATE CANCER EVOLUTION DURING THERAPY IN PROSTATE
CANCER USING PLASMA GENOME SEQUENCING
Naveen Ramesh, M.S.
Advisory Professor: Nicholas Navin, Ph.D.
Investigating genome evolution in response to therapy is difficult in human
tissue samples due to the difficulty in accessing metastatic tumor sites and
logistical challenges of collecting longitudinal samples . To overcome these
issues, we developed an unbiased whole-genome plasma DNA sequencing
approach called PEGASUS that concurrently measures genomic copy number
and exome mutations from archival cryostored plasma samples. This approach
was applied to study longitudinal blood plasma samples from prostate cancer
patients. A molecular characterization of archival plasma DNA from 233
patients and genomic profiling of 101 patients identifie d clinical correlations of
aneuploid plasma DNA profiles with poor survival, increased plasma DNA
concentrations, and lower plasma DNA size distributions. Deep -exome
sequencing and genomic copy number profiling were performed on 23
patients, including 9 patients with matched metastatic tissues and 12 patients
with serial plasma samples. Our data show a high concordance in genomic
alterations between the plasma DNA and metastatic tissue samples,
suggesting the plasma DNA is highly representative of the genomic alterations
in tissues. Longitudinal sequencing of 12 patients with 2–5 serial plasma
samples revealed clonal dynamics and genome evolution in response to
hormonal and chemotherapy. By performing an integrated evolutionary
analysis, minor subclones were identified in 9 patients that expanded in
response to therapy and harbored mutations associated with resistance.
v

Furthermore, we applied PEGASUS to profile a larger cohort of 79 prostate
cancer patients with 2-10 longitudinal samples. A single time point analysis of
49 patients revealed extensive interpatient -heterogeneity and recurrent
aberrations in genes including TP53, PTEN, RB1 and AR. The copy number
and mutational data showed four different evolutionary responses to therapy:
clonal extinction, clonal persistence, intrinsic resistance and partial response .
Survival analysis of these 4 classes show that clonal extinction patients have
a longer survival compared to clonal persistence patients. Overall, t his
dissertation provides an unbiased approach to non-invasively monitor clonal
dynamics in response to therapy in prostate cancer patients, which improved
our understanding of therapeutic resistance in this devastating disease.
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1. INTRODUCTION
As Peter Nowell originally proposed in 1976, tumor evolution is a process that starts
with unfavorable genomic modification(s) to a single normal cell that provides the cell
with a mechanism to evade the immune system and proliferate to develop into a cancer
[1]. These genetic abnormalities that initiate the tumor will be inherited by all the tumor
cells and are known as clonal (truncal) mutations. As these cells divide over time, the
dividing tumor cells constantly accrue genetic abnormalities that are present in a subset
of the tumor cells and are referred to as subclonal mutations. These subclonal
mutations form the basis of genetic diversity within a tumor, also known as intra tumor
heterogeneity (ITH).
Tumor heterogeneity and clonal evolution
ITH in tumor cell morphology was reported a long time ago by pathologist Rudolf
Virchow (late 1800s) [2] as well as the evolutionary biologist Julian Huxley (late 1950’s)
[3] when they suggested the existence of genetic diversity in the tumor as well as the
need to evaluate the extent of ITH. As a tumor progresses, it is treated by clinicians
using various therapeutic agents. When the patients develop resistance to the
treatment, it may be due to the tumor’s adaption to the treatment by accruing additional
mutations that provide fitness advantage (acquired resistance) or result in selection of
the cells that are inherently resistant to the drug (adaptive resistance) [4]. An oncologist
attempts to track tumor progression through a series of blood tests, scans and painful
biopsies to assess tumor’s response to the therapy. The tumors are constantly subject
to selective pressure from internal stimuli such as the immune system as well as
external interventions such as chemotherapy, radiation, nutrition and geographic
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barriers [5]. These selective pressures shape the tumor’s evolutionary trajectory,
resulting in selection of the fittest clones during resistance.
Several studies have shown the significant variability of ITH ranging from 0 to
several thousand mutations in tumors [6, 7]. Although the tumors can have a large
number of genotypic changes, it is only a subset of these changes that exhibit a
phenotypic change and contribute to fitness advantage of the tumor by either assisting
in rapid cell proliferation or reducing cellular death. Therefore, the genotypic changes
that contribute to the fitness advantage will show an increase in frequency through
clonal expansion of the cells [8]. As the sequencing technologies and sample barcoding
approaches evolved coupled with reducing sequencing costs, innovative study designs
and methods have been used by scientist to evaluate ITH [9, 10]. The large body of
literature ranging from single time point bulk tissue analysis [11, 12] and spatial bulk
sequencing [13] to single cell sequencing [14] of the tumor have shown extensive ITH
across many different solid tumor types. However, despite the substantial advances in
the field so far, the issue of how ITH emerges and evolves during treatment and tumor
progression remains a challenge. As ITH evolves within a tumor, it may also reflect
vulnerabilities that can be exploited to target and treat the tumor. Therefore, it is
important to utilize methods to determine the extent of ITH as accurately as possible.
Methods to study tumor heterogeneity
Up until the development of massively parallel sequencing approaches, ITH was
evaluated using methods such as flow cytometry, karyotyping and cytogenetics
methods such as FISH. Flow cytometry was used to identify subpopulations that had
different DNA ploidies in past studies [15-17] while karyotyping was used to identify
subclones with large chromosomal aberrations [18] and DNA-FISH was utilized to
identify cells with differences in copy number of a genes across single cells [19]. These
2

methods are able to separate populations based on copy number broadly using the
overall ploidy or a few genes as markers. Methods such as digital droplet PCR have
been utilized to measure the frequency of a mutation across DNA molecules [20].
Although all these methods can effectively identify subpopulations, they are limited by a
few targeted markers and cannot delineate all clonal subpopulations in an unbiased
way.
The advent of next-generation sequencing has made it possible to sequence the
entire genome of a tumor, thereby making the evaluation of ITH feasible. The evolution
of sequencing technology from Sanger based chemistry to next generation sequencing
(NGS) has enabled a large number of genomic measurements on many tumor samples
in a short period of time feasible at an affordable price [21]. Standard bulk whole
genome sequencing approaches may not have enough resolution to resolve the
subclonal architecture of a tumor, but provides enough data to obtain copy number at
the whole genome level. As NGS sequencing technologies have evolved, scientists
have used innovative approaches such as deep sequencing of specific regions on the
genome such as cancer genes or exonic regions to obtain enough resolution to
delineate the tumor architecture. Several deep sequencing studies have been
conducted to show examples of clonal lineage inference through clustering of the bulk
mutation frequencies [22, 23]. Multi-region sequencing studies have shown that there is
heterogeneity within regions of the tumor and deep sequencing can be used to infer the
evolutionary patterns within the tumor [13]. Taken together, these bulk sequencing
studies suggest that a single time-point or biopsy sample may not accurately capture
the subclonal architecture of the entire tumor cell population accurately.
Over the last two decades, scientists have been able to scale down genomic
analysis to single cell resolution and measure copy number and mutations while
3

increasing the number of cells being sequenced through barcoding strategies [14, 24].
Although the single cell approaches can provide accurate measurements for
delineating the tumor architecture, they are limited by sampling bias arising due to
technical and logistical difficulties such as the limited number of cells (cost), limited
number of tumor sites that can be measured and limited number of longitudinal
samples. Given the evolutionary dynamics of tumors, monitoring disease evolution to
guide therapeutic interventions and to understand evolutionary trajectories of individual
tumors has become a growing research area. In contrast to single cell sequencing
which can provide high resolution on a limited number of samples, it is more
economically feasible to sequence a large number of longitudinal samples, reducing
issues related to single time point samples to decode the tumor architecture.
Resolving the tumor sub-clonal architecture
ITH can be resolved into tumor sub-clones from bulk DNA sequencing
approaches using methods such as PyClone [25], PhyloWGS [26], SciClone [27] and
FastClone [28]. Once ITH has been resolved, methods like CITUP [29] can be utilized
to build phylogenetic trees and resolve the clonal architecture. The inference of a single
time point bulk sequencing sample may lack the resolution of single cell sequencing,
especially when the mutation frequencies of several sub-clones are similar. However,
the power of longitudinal samples during treatment could be possibly utilized to
delineate these sub-clones into different sub-clones by utilizing the changes in mutation
frequencies over time. The number of longitudinal samples could also be increased by
utilizing liquid biopsy approaches. Unlike a core needle biopsy which may be painful
and not practical to perform on a routine basis, the liquid biopsy approach is more
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feasible for collecting many longitudinal samples because blood is drawn from cancer
patients for clinical purposes as part of routine care during each hospital visit.
Non-invasive monitoring of cancer evolution
The liquid biopsy modalities that are commonly used to monitor cancer, assess
ITH and treatment response include circulating tumor cells (CTCs), circulating
leukocytes, circulating tumor RNA (ctRNA) and circulating tumor DNA (ctDNA).
circulating tumor cells (CTCs)
CTCs are cancer cells that shed into the blood stream by the primary and/or
metastatic tumor sites. Given that they could be shed by any of the tumor organ sites or
clones, they often represent multiple metastatic sites and can broadly capture spatial
heterogeneity [30]. However, these cells are extremely rare in the blood and require
enrichment methods that use wphysical, morphological (such as cell size or shape) or
biological properties (eg. EpCAM) of the CTCs [31]. Many CTC studies have been
limited to correlating CTC counts through enrichment methods [32] to understand the
prognostic implications in many cancers. A random sample of CTCs have also been
utilized CTCs for genomic analysis to understand genomic instability [33], response to
therapy [34], spatial heterogeneity [35] and guiding treatment decisions [36] among
other applications. Despite these successful CTC applications, current methods have
not yet reached high sensitivity and specificity for detecting cancer, thereby, limiting the
advantages that CTCs possess to evaluate ITH comprehensively to study tumor
evolution. The technologies that have been developed to pick single CTCs require
manual intervention, thereby, making the CTC picking process and obtaining genomic
measurements extremely laborious and challenging [37].
circulating leukocytes
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circulating leukocytes have been very promising to understand immunological
cancer heterogeneity by surface immunoprofiling and T cell receptor (TCR) profiling.
For instance, a lung cancer study was able to show that spatially heterogeneous TCR
maybe a reflection of the mutational heterogeneity [38]. This study was conducted in
tissue samples and there is a lack of understanding about the role of circulating
lymphocytes in patients. As technologies have been advancing, it has become possible
to identify subsets of leukocytes through approaches like mass cytometry [39]. This
data has been primarily utilized to understand the predictive role of specific leukocytes
such as CD56+ T cells in patients undergoing therapy [40]. Although the circulating
leukocytes are promising, the approaches haven’t been standardized and they typically
require expensive technology for isolation and profiling.
circulating tumor RNA (ctRNA)
Cancer cells shed RNA into the blood stream through different mechanisms.
Some of these mechanisms involve the utilization of micro vesicles known as
exosomes, which are cell-derived extracellular vesicles released by different cell types,
including immune cells and cancer cells [41-43]. These exosomes have been shown to
play a role in assisting the tumor through processes such as proliferation and
progression [41]. ctRNA has been shown to have clinical value by providing a marker to
monitor tumor progression and overall survival. For instance, in prostate cancer the
presence of AR spice variant 7 (AR-V7) is associated with a shorter response time [44].
The major limitation of ctRNA has been the contamination with circulating normal RNA.
This issue is particularly compounded in RNA due to its instable nature as well as lower
abundance compared to DNA [45]. Additionally, non-coding RNAs are more prevalent
in the blood compared to mRNA, thereby, making unbiased inferences about the tumor
challenging.
6

circulating tumor DNA (ctDNA)
The cfDNA is released into the blood by biological processes such as apoptosis,
necrosis or active secretion [46]. cfDNA fragments can be released by both tumor
(known as ctDNA) and normal cells. Therefore, an isolation process contains fragments
from both of these sources at various proportions depending on factors such as stage
of the disease, treatment status and metastatic sites. Despite the low abundance of
cfDNA even in patients with advanced disease, they have several advantages
compared from a research and clinical perspective. In contrast to tissue-based
monitoring and the other non-invasive biomarkers, cfDNA processing doesn’t require
expensive equipment and can be easily isolated in the laboratory and stored at -80C.
As blood can be collected, processed and store with relative ease, cfDNA allows for
longitudinal sample collection using the plasma layers. Blood is collected routinely for
clinical purposes routinely and it is collected more frequently than tissue samples.
cfDNA analysis is also possible at time points when tissue collection isn’t feasible and
when it may not be practical to biopsy the tissue because of the risks involved (eg.
serial bone biopsies). Although there is variability in the ctDNA fraction, it has been
shown in several cancers including breast and prostate cancer that just the mere
presence of a high ctDNA fraction correlates with poor outcome [47, 48]. ctDNA
genomics have also been evaluated in several studies suggesting that aberrations
detected in the blood correlates with a single metastatic biopsy. However, these studies
also document the presence of mutations in the cfDNA that were not detected in the
matched biopsy sample [49-51]. For example, in a breast cancer study, ESR1
mutations in the ctDNA that were not detected in the tissue sample were associated
with resistance to endocrine therapy [52]. These studies suggest that sampling bias
within and between tumor sites could be mitigated by utilizing ctDNA to monitor and
7

understand the biology of the disease. In addition to detecting specific mutations,
several studies have suggested that cfDNA can be used to detect sub-clonal mutations
and estimate their variant allele frequencies (VAF). For example, two studies show that
a subclonal selection of PIK3CA [53] and the VAF of a HER2 mutation could be used to
predict the progression free survival (PFS) [54]. Taken together, this literature suggest
that cfDNA may be a sensitive and efficient approach to effectively monitor the
evolution of cancer during therapy. The advantages of cfDNA outweigh the limitations if
the issue related to low abundance can be resolved.
cfDNA approaches to monitor cancer evolution
Broadly, cfDNA monitoring methods can be classified into 3 categories:
1. Targeted quantification of hotspot mutations
2. Targeted sequencing of cancer genes
3. Unbiased whole-genome sequencing
Targeted quantification of hotspot mutations
One of the most common approaches to monitor the tumor non-invasively has
been through the utilization of known tumor mutations. In this approach, primers are
designed for the known hotspot mutations and/or mutations previously detected on the
patients’ tissue samples. These mutations are monitored for increases or decreases of
the mutation allele frequency longitudinally to assess whether patient is responding or
developing resistance to treatment over time [55, 56]. The major advantages of this
method include high sensitivity and high depth of sequencing while potentially
maintaining low cost of the performing the experiment. However, this method is not
useful to understand new resistance mechanisms as the primers will not include those
regions.
Targeted sequencing of cancer genes
8

The second approach utilizes probes for a cancer gene panel. Examples of this
approach includes commercial assays launched by companies such as Guardant [57]
and Foundation Medicine [58]. These panels consist of a number of genes that are
commonly mutated as well as those genes where the alterations can be targeted.
These panels can be used to achieve high sensitivity, determine actionable point
mutations and obtain an estimate of whether the genes have been amplified or deleted.
These commercial panels provide tremendous value to the clinicians as the results can
be used to match the patients to availability therapy options. However, in the context of
understanding the tumor as a whole, these panels cannot identify aberrations’ outside
the gene panel. These genes maybe important to understand tumor substructure as
well as to identify resistance mechanisms that are not yet understood.
Unbiased whole-genome sequencing methods
The unbiased genomic approach refers to the concept of identifying aberrations
across the whole genome instead of targeting tumor spots or cancer genes. This
approach is being increasingly used in the field to evaluate both copy number and point
mutations without prior knowledge of the patients’ tissue genomics [47, 48]. This
approach may be quite effective from a research perspective because it can provide a
large number of genomic markers that are necessary to understand the clonal evolution
and understand new mechanisms of resistance. The copy number estimates from
whole genome data maybe more reliable compared to inference from a targeted
approach. The unbiased sequencing approach could be expensive depending on the
exome sequencing depth as well as the number of samples/time points, but it provides
a large number of markers necessary to deconvolute the tumor architecture.
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Prostate cancer and its challenges
Prostate cancer and its earliest treatment in the form of surgical castration has
been known from the time of ancient Egyptians [59]. Over the last 3-4 decades,
prostate specific antigen (PSA) test has been used for initial diagnosis and monitoring
of the disease. PSA is an antigen that is produced by the normal prostate but gets
released into the blood when the prostate gets disrupted during processes like cancer
[60]. Although this test does provide an indication about the cancer, it is far from a
perfect to accurately predict when cancer and treatment response. If the patients have
an elevated PSA, biopsies are taken to grade the tumor using the Gleason scoring
system [61, 62]. The biopsies are also used to classify the stage of the cancer using
the TNM classification. This classification is based on organ-confined to fully invasive
(T1–4), with or without lymph node involvement (N0 or 1), and the presence and
degree of distant metastases (M0 and 1a–c) [63]. Once the disease status is assessed
by the oncologist, the prostate cancer patient is treated with surgical or biochemical
castration of the prostate. Biochemical castration is done by androgen deprivation
therapy (ADT) such as Lupron to inhibit production of testosterone and stop the
proliferation of prostate cancer cells. However, these tumors adapt to low levels of
testosterone and develop resistance to ADT. At this stage the oncologist treats the
patient with second generation hormone agents such as abiraterone and enzalutamide
followed by aggressive therapies such as docetaxel, cabazitaxel, carboplatin, radium223, sipulecel-T among others to prevent the proliferation of the prostate cancer at the
primary and the metastatic sites, the common metastatic site being the bone.
The current paradigm of prostate cancer diagnosis and management has
challenges from a clinical and research perspective. Advanced PC (mPC) has the
propensity to metastasize to the bone. In several mPC patients, bone can be the only
10

metastatic site and they may appear like osteoblastic lesions (bone forming) in about
50% of the patients [64-66]. The bone lesions are identified by scans but it is still a
challenge to quantify response or progression to therapy. The bone forming nature of
the disease makes it challenging to obtain metastatic samples, thereby making the
collection of longitudinal samples extremely challenging and quite often not practical.
The difficulty of routine sample collection in mPC makes it challenging to understand
tumor evolution and mechanisms that drive bone metastasis. Studies have utilized
single time point samples to identify driver genes in mPC such as NEAT1, FOXA1,
CHD1 and BRCA2 [67]. This study was able to identify genes that are druggable
targets for druggable and investigational therapies. Several other studies have been
able to utilize biopsy samples to infer mPC evolutionary history and elucidate altered
genes (AR, TP53, RB, SPOP, PTEN, and others) and signaling pathways contributing
to prostate cancer progression [68]. However, the presence of low-frequency variants
and ITH in mPC has been clearly shown [69]. Due to this ITH and lack of longitudinal
tissue samples primarily from the bone, disease and patient classification has remained
a challenge. There is an ongoing need to identify patients who would relapse, patients
would require aggressive therapy as well as monitor resistance real time and predict
tumor progression. Although it is challenging to collect metastatic samples regularly to
meet these needs, blood is collected from the mPC patients for clinical purposes
routinely. The plasma isolated from this blood contains varying proportions of ctDNA
which could be used to identify clones that are preferentially selected during treatment.
These clones maybe providing fitness advantage to the tumor and may contain
genomic information to identify pathways contributing to resistance as well as
vulnerabilities that could potentially be targeted with existing therapies.
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Therefore, the goal of this dissertation is to develop a cfDNA sequencing method
that can provide high quality copy number and point mutation data from archival
plasma samples, validate the results with matched biopsy samples, investigate the
evolutionary dynamics of mPC and classify patients into clinically meaningful
subgroups.
Significance
This work is expected to have a major impact on the treatment of cancer
patients specifically, mPC patients, by providing a novel non-invasive technology to
profile mutations and CNAs from the blood plasma either real-time or retrospectively.
PEGASUS approach has the potential to identify resistant clones as well as therapeutic
targets for overcoming resistant disease.
2. DECODING THE EVOLUTION OF PROSTATE CANCER DURING THERAPY
USING PLASMA GENOME SEQUENCING
This chapter consists of text written in the following Genome Biology paper:
Ramesh N, Sei E, Tsai PC, Bai S, Zhao Y, Troncoso P, Corn PC, Logothetis C, Zurita
AJ, Navin NE. Decoding the evolutionary response to prostate cancer therapy by
plasma genome sequencing. Genome Biol 21, 162 (2020).
https://doi.org/10.1186/s13059-020-02045-9
Copyright information from the Genome Biology website:
•

Copyright on any open access article in a journal published by BioMed Central is
retained by the author(s).

•

The Creative Commons Attribution License 4.0 formalizes these and other terms
and conditions of publishing articles.
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Background
Clonal evolution has been challenging to study in tumor tissue obtained from
cancer patients, particularly in specimens collected from a single point in time [2, 7, 70].
While a small number of studies were able to collect serial core biopsies for genomic
profiling [71], those studies still suffered from small amounts of tumor tissue availability
and spatial sampling bias. Moreover, tumor biopsies are invasive clinical procedures
with potential for complications and have significant costs [72, 73]. An alternative noninvasive approach involves using liquid biopsies, including circulating tumor cells [7476] and cell-free DNA (cfDNA) [47, 77-79]. Blood samples collected over time during
the course of treatment provide a unique opportunity to infer tumor evolution [80].
cfDNA is particularly useful for clinical applications due to the logistical advantage of
straightforward processing and the ability to cryostore materials for future analysis [8183]. However, a major limitation has been that most cfDNA assays were developed to
analyze targeted cancer gene panels and have therefore measured a limited number of
CNAs and mutations [57, 84-86]. Resolving intratumor heterogeneity and inferring
clonal evolution requires measuring a large number of unbiased genomic markers,
which targeted panels cannot provide.
A few studies have made initial progress towards performing unbiased exome
sequencing of cfDNA in gastrointestinal cancers [87] and prostate cancer (PC) [47], or
whole-genome copy number profiling of triple-negative breast cancer patients [48].
Building on those early studies, we have developed a method called PEGASUS
(Plasma Exome and Genome Analysis by Size-selection Unbiased sequencing) to
profile both genome-wide CNA and exome-wide mutations (~ 25,000 genes)
simultaneously from archival cryostored plasma or serum DNA samples. In contrast to
targeted methods [88-90], PEGASUS involves selection of small DNA fragments that
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contain higher tumor content relative to high molecular weight DNA from WBCs present
in cryostored blood fractions. These characteristics make PEGASUS ideally suited for
unbiased discovery of genomic markers and for the investigation of clonal evolution in
response to therapy, when applied to longitudinal blood collections.
Comprehensive genomic studies have identified multiple recurrently altered
genes (AR, TP53, RB, SPOP, PTEN, and others) and signaling pathways in metastatic
prostate cancer (mPC) [69], but have also revealed the existence of many lowfrequency variants and significant inter-patient heterogeneity. Moreover, PC is unique
among solid tumors due to its dependence on androgen receptor-regulated pathways
for progression and its high propensity to metastasize to the bone (often the only site of
progression). The vast majority of previously untreated or castration-sensitive prostate
cancer (CSPC) respond to initial androgen deprivation therapy (ADT), but the disease
invariably adapts and progresses to lethal castration-resistance prostate cancer
(CRPC) [91]. Treatment strategies for CRPC patients are limited and include advanced
hormonal therapies and taxane-based chemotherapy, but no molecular markers have
yet been established to guide their application and timing of treatment. Because of the
bone dominance of metastatic prostate cancer (mPC), bone biopsies are most
frequently needed for pathological and molecular characterization, but these are
uncomfortable and difficult to perform procedures that often result in minute amounts of
tumor tissue that is not suitable for genomic analysis. As a result, mPC presents a
unique opportunity for liquid biopsy genomics to investigate heterogeneity and clonal
evolution over time in the context of therapy.
Results
PEGASUS method
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While prospective studies typically use Streck tubes to collect plasma, most
archival plasma samples have historically been collected in EDTA tubes or subjected to
a gradient treatment such as Ficoll prior to cryostorage. In contrast to Streck tubes
(which include a fixative), the usage of EDTA/Ficoll medium often leads to
contamination by high molecular weight DNA fragments that are released from the
WBC during sample processing. To address this problem, PEGASUS was designed to
isolate low molecular weight DNA fragments (< 1000 bp), which is done prior to the
construction of low-input libraries for whole-genome sequencing (WGS) of copy
number alterations (CNAs) and exome mutation profiling (Fig. 1a, the “Methods”
section). After three rounds of high-speed centrifugation to remove residual WBC, the
archival plasma samples are subjected to size selection by column purification. The
remaining low molecular weight DNA is used for quality control (QC) to determine the
plasma DNA concentration and molecular size of the DNA fragments. Samples that
pass QC are used to construct low-input NGS libraries, which are split into two parallel
reactions: (1) copy number profiling by WGS at sparse (0.1X) coverage depth and (2)
exome sequencing at high coverage depth (150X tumor, 60X normal) to detect somatic
mutations and indels (the “Methods” section). NGS libraries are generated in parallel
from WBCs for exome capture to serve as a matched normal reference of germline
variants to distinguish somatic mutations. This protocol can also be performed on fresh
blood samples collected in Streck tubes.
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Fig. 1: PEGASUS whole-genome plasma sequencing approach and molecular
properties of cfDNA
a Workflow for the PEGASUS whole-genome plasma DNA sequencing
approach. b Distribution of total cfDNA concentrations (nanograms) in the prostate
cancer patients, with the dotted line showing the QC threshold (< 2 ng). c Comparison
of cfDNA concentrations (ng/mL) between diploid and aneuploid genomic cfDNA
profiles. d Distribution of cfDNA fragment sizes (bp). e Comparison of the distribution of
cfDNA fragment sizes in basepairs between diploid and aneuploid genomic cfDNA
profiles. f Distribution of the somatic mutation allele frequencies (MAFs) among the 23
plasma and 9 metastatic tissue samples. Significance in c and e was calculated using
the Wilcoxon rank sum test. Red dots in c and e represent mean values
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Molecular properties of cfDNA and clinical correlations
We performed QC of cfDNA in 233 cryostored archival plasma samples
collected from PC patients at MD Anderson by measuring the size and concentration,
including 79 patients with CSPC and 154 patients with CRPC (Fig. 1b). QC indicated
that 130 of the 233 patients (55.8%) had sufficient cfDNA (≥ 2 ng total) for construction
of NGS libraries using PEGASUS. The QC data showed a wide range in the total
amounts of low molecular weight cfDNA (0–5280 ng) across the patients, including a
subset of 29 patients (12.4% of the total) with very high amounts of total cfDNA
(≥ 20 ng) (left side, Fig. 1b). The median cfDNA concentrations in CSPC (1.25 ng/mL)
and CRPC patients (0.84 ng/mL) were not significantly different (p = 0.29, Wilcoxon
test). However, 24 CSPC patients (30.4%) had < 0.5 ng of detectable plasma DNA
compared to only 5 (3.2%) of the CRPC patients (Fig. 1b and Fig. 4a), suggesting that
a larger proportion of CRPC patients could potentially be used for genomic profiling
using PEGASUS. We performed low-pass WGS of 101 plasma samples to understand
how diploid and aneuploid genomic copy number profiles correlate with cfDNA
properties. This data showed that cfDNA concentrations were significantly higher in
patients with aneuploid genomes compared to patients with diploid plasma copy
number (p = 0.00014, Wilcoxon rank sum test) (Fig. 1c).
Analysis of the cfDNA fragment sizes showed a mean molecular size of
146.6 ± 1.29 bp (SEM) across the patients, with a bimodal cfDNA size distribution
(Fig. 1d, Fig. 2). PC patients with diploid copy number had significantly (p = 0.0013,
Wilcoxon rank sum test) larger cfDNA fragment sizes (mean 154 ± 1.66 bp) compared
to patients with aneuploid profiles (mean 142 ± 2.91 bp) (Fig. 1d, e). These numbers
are consistent with previous reports on plasma DNA fragment size distributions for
circulating tumor DNA (ctDNA) compared to cfDNA that was isolated from normal cells
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[92, 93], suggesting that the tumor cells are not shedding large amounts of DNA into
the plasma. Notably, a subset of patients had additional peaks at double and triple the
mean cfDNA fragment size, possibly indicating that the DNA was protected by multiple
nucleosomes, rather than a single nucleosome detected in most PC patients (Fig. 2ad).

Fig. 2: Size distributions of cfDNA in multiple nucleosomes from representative patients
Tape station traces of cfDNA size distributions in 4 representative prostate cancer
patients. (a) A patient with no cfDNA peak identified in the plasma, (b) a patient with a
single nucleosome peak with a mean size of 146bp, (c) a patient with double
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nucleosome peaks identified at ~146bp and ~292bp, and (d) a patient with triple
nucleosome peaks identified at ~146bp, ~292bp and ~438bp. (e) Distribution of cfDNA
concentration (ng/ml) after purification of 4 samples with 4 experimental replicates, with
the mean (solid circles) and standard deviation indicated.
While most of the 233 patient samples used for QC were from single-timepoint
blood samples, there were 9 patients with matched metastatic tissues and 12 patients
with longitudinal blood samples collected during therapy that were selected for genomic
CNA profiling and exome sequencing by PEGASUS. To test the variability in ctDNA
concentration after isolation, we performed 4 experimental replicates from 4 test
plasma samples, which showed only minor variations in the final concentrations of
ctDNA (Fig. 2e). Analysis of the somatic exome mutation allele frequency (MAF)
showed a median MAF of 0.17 for the aneuploid cfDNA samples, which was slightly
lower than the MAF detected in matched metastatic tumor tissues (median 0.3)
(Fig. 1f). Notably, plasma DNA with diploid genomic copy number profiles showed the
lowest MAF (median 0.08), suggesting that the contribution of cfDNA from normal cells
was high in these patients, with limited ctDNA.
Clinical correlations with plasma DNA properties
Survival analysis revealed that CRPC patients with total cfDNA < 2 ng had
significantly longer overall survival (OS) than patients with total cfDNA ≥ 2 ng (median
22.2 vs 13.3 months, p = 0.0022, log-rank test) (Fig. 3a, Fig. 4). Furthermore, patients
with diploid cfDNA CNA profiles had longer OS than patients with aneuploid cfDNA
CNA profiles (median 21.05 vs 12.6 months, p = 0.031, log-rank test) (Fig. 3b, Fig. 4).
We next investigated associations between cfDNA concentrations and clinical
parameters. Patients with accelerated PC growth had higher cfDNA levels (n = 94)
compared to those with protracted kinetics of progression (n = 139; p = 0.00024,
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Wilcoxon rank sum test) (Fig. 3c). Furthermore, PC patients with high disease volume
(n = 128) had significantly higher cfDNA levels compared to patients with low disease
volume (n = 65; p = 0.018, Wilcoxon rank sum test) (Fig. 3d). Notably, cfDNA
concentrations were not significantly different (p = 0.4642, Wilcoxon rank sum test) in
patients with histologic low grade groups 1–2 (n = 54) compared to high grade
groups 3–5 (n = 164) on diagnosis (Fig. 4d). By comparing local and distant
metastases, PC patients with bone (n = 132) or visceral metastasis (n = 41) had
respectively higher cfDNA concentrations than patients with lymph node metastasis
only (n = 30; p = 0.042 and p = 0.0099 for bone and visceral metastasis, respectively, vs
lymph node) (Fig. 4e). Similarly, PSA levels had a low correlation with cfDNA
concentrations (R = 0.12, p = 0.073) (Fig. 4f). Finally, we utilized all the clinical and
genomic factors as predictors for the OS and progression-free survival (PFS) using the
univariate and multivariate Cox regression model in a subset of 70 patients that had
consistent clinical variables available for all of the parameters we tested. Based on the
survival analysis, we found that ploidy has significant independent and joint predictive
power for OS, with significant joint predictive power for PFS (Table 1). Collectively,
these data suggest that higher cfDNA in the plasma and genomic aneuploidy associate
with faster mPC progression and a shorter survival of PC patients.
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Table S1 – Cox proportional hazards regression model (a) Overall and (b) Progression-Free Survival Analysis
using clinical and genomic factors as predictors with (1) total cfDNA as a predictor, (2) ploidy of the cfDNA as a
predictor, (3) total cfDNA and ploidy of cfDNA as predictors, (4) total cfDNA, ploidy of cfDNA and its interaction as
predictors, (5) total cfDNA, ploidy of cfDNA, cfDNA fragment size, disease volume and type of progression.
a. Overall Survival (OS)
n= 70, number of events= 53
1. OS (outcome); total cfDNA (< or >= 2ng) (predictor)
predictors
total_cfDNA_>=2ng

coef
exp(coef) se(coef)
lower 0.95 upper 0.95 z
0.5772
1.781
0.4374
0.7556
4.198

1.319

Pr(>|z|)
0.187

2.351

Pr(>|z|)
signifiance
0.0187 *

Concordance= 0.55 (se = 0.026 )
Likelihood ratio test= 2 on 1 df, p=0.2
Wald test = 1.74 on 1 df, p=0.2
Score (logrank) test = 1.79 on 1 df, p=0.2
2. OS (outcome); ploidy of the cfDNA (Diploid vs Aneuploid) (predictor)
predictors
Aneuploid

coef
exp(coef) se(coef)
lower 0.95 upper 0.95 z
0.8009
2.2275
0.3407
1.142
4.344

Concordance= 0.594 (se = 0.031 )
Likelihood ratio test= 6.34 on 1 df, p=0.01
Wald test = 5.53 on 1 df, p=0.02
Score (logrank) test = 5.82 on 1 df, p=0.02
3. OS (outcome); total cfDNA (< or >= 2ng) and ploidy of the cfDNA (Diploid vs Aneuploid) (predictors)
predictors
total_cfDNA_>=2ng
Aneuploid

coef
0.407
0.7435

exp(coef) se(coef)
lower 0.95 upper 0.95 z
1.5023
0.4434
0.63
3.583
2.1033
0.345
1.07
4.136

0.918
2.155

Pr(>|z|)
signifiance
0.3587
0.0312 *

Concordance= 0.614 (se = 0.034 )
Likelihood ratio test= 7.27 on 2 df, p=0.03
Wald test = 6.27 on 2 df, p=0.04
Score (logrank) test = 6.59 on 2 df, p=0.04
4. OS (outcome); total cfDNA (< or >= 2ng), ploidy of the cfDNA (Diploid vs Aneuploid) and interaction of total cfDNA and ploidy of cfDNA
(predictors)
predictors
coef
exp(coef) se(coef)
lower 0.95 upper 0.95 z
total_cfDNA_>=2ng
0.5842
1.7935
0.7851
0.3849
8.356
Aneuploid
0.966
2.6273
0.8689
0.4785
14.426
total_cfDNA_>=2ng*Aneuploid -0.2651
0.7671
0.9445
0.1205
4.885

0.744
1.112
-0.281

Pr(>|z|)
0.457
0.266
0.779

Concordance= 0.614 (se = 0.034 )
Likelihood ratio test= 7.35 on 3 df, p=0.06
Wald test = 6.12 on 3 df, p=0.1
Score (logrank) test = 6.59 on 3 df, p=0.09
5. OS (outcome); total cfDNA (< or >= 2ng), ploidy of the cfDNA (Diploid vs Aneuploid), cfDNA fragment size, disease volume (low vs
intermediate and high), type of progression (protracted vs accelerated) and metastatic sites (none/prostate vs lymph node, bones +/- lymph
nodes and visceral+) (predictors)
predictors
coef
exp(coef) se(coef)
lower 0.95 upper 0.95 z
Pr(>|z|)
signifiance
total_cfDNA_>=2ng
0.409977 1.506784 0.457258
0.61494
3.692
0.897
0.3699
Aneuploid
0.857022 2.356133
0.40298
1.0695
5.191
2.127
0.0334 *
cfDNA_fragment_size
0.01183
1.0119 0.010633
0.99103
1.033
1.113
0.2659
disease_volume_intermediate
0.2379 1.268583 0.856011
0.23696
6.791
0.278
0.7811
disease_volume_high
0.271155 1.311478 0.833771
0.25589
6.722
0.325
0.745
progression_accelerated
0.150931 1.162917 0.355396
0.57948
2.334
0.425
0.6711
grade_high
NA
NA
0 NA
NA
NA
NA
LN
0.332071 1.393852 0.810142
0.28485
6.82
0.41
0.6819
Bones+/-LN
-0.017465 0.982687 0.746171
0.22765
4.242
-0.023
0.9813
Visceral+
-0.827227
0.43726
0.7982
0.09148
2.09
-1.036
0.3
PSA
0.000376 1.000376
0.00025
0.99989
1.001
1.504
0.1326
Concordance= 0.667 (se = 0.039 )
Likelihood ratio test= 16.69 on 10 df, p=0.08
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Wald test = 15.45 on 10 df, p=0.1
Score (logrank) test = 16.47 on 10 df, p=0.09

b. Progression-Free Survival (PFS)
n= 70, number of events= 69
1. PFS (outcome); total cfDNA (< or >= 2ng) (predictor)
predictors
total_cfDNA_>=2ng

coef
exp(coef) se(coef)
lower 0.95 upper 0.95 z
0.2171
1.2425
0.3321
0.648
2.382

0.654

Pr(>|z|)
0.513

1.716

Pr(>|z|)
0.0861

Concordance= 0.528 (se = 0.027 )
Likelihood ratio test= 0.45 on 1 df, p=0.5
Wald test = 0.43 on 1 df, p=0.5
Score (logrank) test = 0.43 on 1 df, p=0.5
2. PFS (outcome); ploidy of the cfDNA (Diploid vs Aneuploid) (predictor)
predictors
Aneuploid

coef
exp(coef) se(coef)
lower 0.95 upper 0.95 z
0.4749
1.6079
0.2767
0.9348
2.766

Concordance= 0.572 (se = 0.029 )
Likelihood ratio test= 3.15 on 1 df, p=0.08
Wald test = 2.95 on 1 df, p=0.09
Score (logrank) test = 3 on 1 df, p=0.08
3. PFS (outcome); total cfDNA (< or >= 2ng) and ploidy of the cfDNA (Diploid vs Aneuploid) (predictors)
predictors
total_cfDNA_>=2ng
Aneuploid

coef
exp(coef) se(coef)
lower 0.95 upper 0.95 z
0.02602
1.02636
0.35158
0.5153
2.044
0.4677
1.59631
0.2933
0.8984
2.836

0.074
1.595

Pr(>|z|)
0.941
0.111

Concordance= 0.576 (se = 0.034 )
Likelihood ratio test= 3.15 on 2 df, p=0.2
Wald test = 2.95 on 2 df, p=0.2
Score (logrank) test = 3 on 2 df, p=0.2
4. PFS (outcome); total cfDNA (< or >= 2ng), ploidy of the cfDNA (Diploid vs Aneuploid) and interaction of total cfDNA
and ploidy of cfDNA (predictors)
predictors
coef
exp(coef) se(coef)
lower 0.95 upper 0.95 z
total_cfDNA_>=2ng
0.4437
1.5585
0.5315
0.5499
4.417
Aneuploid
1.0711
2.9186
0.6161
0.8725
9.763
total_cfDNA_>=2ng*Aneuploid -0.7713
0.4624
0.6936
0.1187
1.801

0.835
1.739
-1.112

Pr(>|z|)
0.4038
0.0821
0.2662

Concordance= 0.586 (se = 0.033 )
Likelihood ratio test= 4.38 on 3 df, p=0.2
Wald test = 4 on 3 df, p=0.3
Score (logrank) test = 4.15 on 3 df, p=0.2
5. PFS (outcome); total cfDNA (< or >= 2ng), ploidy of the cfDNA (Diploid vs Aneuploid), cfDNA fragment size, disease volume (low vs
intermediate and high), type of progression (protracted vs accelerated) and metastatic sites (none/prostate vs lymph node, bones +/- lymph
nodes and visceral+) (predictors)
predictors
coef
exp(coef) se(coef)
lower 0.95 upper 0.95 z
Pr(>|z|)
signifiance
total_cfDNA_>=2ng
0.119201 1.126597 0.376241
0.5389
2.355
0.317
0.7514
Aneuploid
0.794438 2.213197 0.316764
1.1896
4.118
2.508
0.0121 *
cfDNA_fragment_size
0.009014 1.009055 0.009448
0.9905
1.028
0.954
0.34
disease_volume_intermediate-0.001088 0.998913 0.870019
0.1815
5.497
-0.001
0.999
disease_volume_high
-0.327994 0.720367 0.889385
0.126
4.117
-0.369
0.7123
progression_accelerated
0.085318 1.089064 0.300115
0.6048
1.961
0.284
0.7762
grade_high
NA
NA
0 NA
NA
NA
NA
LN
0.793291
2.21066 0.809597
0.4523
10.806
0.98
0.3272
Bones+/-LN
1.090723 2.976425
0.75464
0.6782
13.063
1.445
0.1484
Visceral+
0.797612 2.220233 0.772719
0.4883
10.096
1.032
0.302
PSA
-0.00028 0.999721 0.000316
0.9991
1
-0.884
0.3767
Concordance= 0.611 (se = 0.038 )
Likelihood ratio test= 10.8 on 10 df, p=0.4
Wald test = 10.39 on 10 df, p=0.4
Score (logrank) test = 10.7 on 10 df, p=0.4

Table 1: Cox proportional hazards regression model
(a) Overall and (b) Progression-Free Survival Analysis using clinical and genomic
factors as predictors with (1) total cfDNA as a predictor, (2) ploidy of the cfDNA as a
predictor, (3) total cfDNA and ploidy of cfDNA as predictors, (4) total cfDNA, ploidy of
cfDNA and its interaction as predictors, (5) total cfDNA, ploidy of cfDNA, cfDNA
fragment size, disease volume and type of progression.
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Fig. 3: Survival analysis and correlation of cfDNA concentration with clinical features
a Kaplan-Meier overall survival plot for prostate cancer patients with total plasma
DNA < 2 ng and total plasma DNA ≥ 2 ng. b Kaplan-Meier overall survival plot for
patients with aneuploid and diploid cfDNA CNA profiles. c Comparison of the
distribution of cfDNA concentration between accelerated and protracted
progressors. d Distribution of cfDNA concentrations (ng/mL) between patients with low,
intermediate, and high volume of disease. Significance for the survival analysis
in a and b was calculated with the log-rank test, while the significance of the box plots
in c and d was calculated using the Wilcoxon rank sum test. Red dots
in c and d represent mean values
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Fig. 4: Correlation of plasma DNA parameters with clinical features
(a) Comparison of cfDNA concentrations between CSPC and CRPC patients. (b)
Kaplan-Meier curve of progression-free survival for patients with total plasma DNA <2
ng and total plasma DNA ≥ 2 ng. (c) Kaplan Meier progression-free survival plot for
patients with aneuploid and diploid cfDNA CNA profiles.(d) Comparison of the
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distributions of cfDNA concentrations (ng/mL) between patients with low (GS=6-7) and
high grade (GS=8-10) as defined by Gleason scores. (e) Comparison of the
distributions of cfDNA concentration (ng/mL) between patients with active disease in
the primary site (prostate), lymph node (lym), bone (oss) and/or visceral metastasis (f)
cfDNA concentrations (ng/mL) compared to PSA values (ng/mL), with correlation
values calculated by pearson correlation coefficient. Significance for the survival
analysis in panels (b,c) was calculated with the log-rank test, while the signficance of
the plots in panels (a,d,e) was calculated using the wilcoxon rank sum test. Red dots in
panels (a,d,e) represent mean values.
Whole-genome profiling of single-timepoint samples
We applied PEGASUS to obtain integrated genomic CNA and exome mutation
profiling of single-timepoint plasma samples from 8 CRPC patients (Fig. 5, Fig. 6).
These patients had a mean 34.8 ± 6.49 (SEM) CNAs and 55.6 ± 14.99 (SEM) point
mutations and 16 ± 3.15 (SEM) insertion-deletions (indels). However, two of the
patients (P1, P4) had a much higher mutation burden (106 and 139 mutations,
respectively) (Fig. 5a). Recurrent CNAs identified included amplifications in MYC (8q)
in all 8 patients and in AR (Xq) in 4 patients, as well as losses in RB1 (13q) in 7
patients, TP53 (17p) in 4 patients, and APC (5q) in 3 patients (Fig. 5c, Fig. 6a). Point
mutations were identified in GNAS, NCOA5, EVL, and BIRC6, while indels were found
in BRCA2, APC, TP53, and FOXA1 among other cancer genes. Our unbiased analysis
also identified CNAs and mutations in genes that have not previously been associated
with mPC progression (Fig. 5c, Fig. 6b). The overall distribution of the CNAs among the
8 single-timepoint samples shows a negative binomial distribution, with a majority of the
CNA genomic sizes < 50,000 kb (Fig. 6c). On a per-patient basis, the chromosome
length of the CNAs are generally < 50,000 kb while a subset of CNAs have larger size
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distributions (Fig. 6d). This data demonstrates the technical feasibility of using
PEGASUS to perform unbiased genomic profiling and detect both recurrent and
infrequent PC aberrations in cfDNA.

Fig. 5: cfDNA sequencing of single-timepoint samples
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a Global number of CNAs detected in each of 8 patients. b Mutation burden quantified
from exome data of 8 patients, including all exonic mutations. c Genomic copy number
ratio and segmentation plots of plasma DNA from 4 prostate cancer patients, with
annotations of prostate cancer genes amplified shown in red boxes and lost shown in
blue boxes. d Circos plots of CNAs, indels, and point mutations for the plasma DNA of
the 4 patients, with prostate cancer genes annotated in the outer ring
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Fig. 6: Additional Patients with Single Timepoint Plasma Samples
(a) Genomic copy number ratio and segmentation plots of cfDNA from 4 prostate
cancer patients, with annotations of prostate cancer genes amplified in red boxes and
lost in blue boxes. (b) circos plots of CNAs, indels and point mutations for the plasma
DNA of the 4 patients with annotations of prostate cancer genes labeled in the outer
ring. (c) box plot representing the fraction of genome with CNAs. The copy neutral state
has been set to the median segmentation value. (d) Distribution of the CNA lengths
(kb). The copy neutral state has been defined as the median segmentation value.
Tumor DNA concordance in plasma and metastatic tissue
To investigate the concordance of genomic events between the cfDNA and
metastatic tumor tissues, we applied PEGASUS to 9 CRPC patients with matched
tissue specimens obtained from different metastatic organ sites (Fig. 7a). Global
genomic analysis showed that the CNA burden in plasma and metastatic tumor tissue
was highly correlated (mean r = 0.9) in most patients (P8–P12) (Fig. 7b). However, in 4
patients (P5, P6, P7, P13), the CNA burden in the plasma was lower than the
corresponding tumor tissue (mean r = 0.6), suggesting that some tumor clones in the
metastatic sites did not shed sufficient DNA into the blood for detection (Fig. 7b).
Similarly, the total mutation burden was highly concordant between the matched cfDNA
and metastatic tissues (51–96%), including two patients (P5 and P10) who had a very
large number of somatic mutations (> 200) in both the blood and tissue, consistent with
a hypermutator genotype [94, 95] (Fig. 7c). In P10, deletions in both MSH2 and MSH6
were detected, while in P5, an MLH1 deletion was identified, which may have
contributed to the high mutation burden in these patients (Fig. 8a; Fig. 8d).
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Fig. 7: Concordance of plasma DNA and metastatic tissue samples
a Metastatic organ site location of the matched tissue samples. b Total number of
CNAs identified across the 9 metastatic patients. c Mutation burden quantified from
exome data of 9 patients, including both non-synonymous and synonymous exonic
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mutations. d–f Genomic copy number data and exome mutations for 3 patients with
matched metastatic tissue samples, with prostate cancer genes labeled.
Further analysis showed that most CNAs, including amplification in AR and
deletion in PTEN in P8, amplifications in ELF2 and MYC in P9, and amplifications
in MYC and CCND1 in P11, were concordant in the plasma and tumor tissues (Fig. 7d–
f). However, we also found a small number of discordant CNAs that were exclusive to
the metastatic tumor tissue (P6) or the cfDNA (P8, P9, P12, and P13). P6 had a focal
amplification in 12p21 (3.72 mb, including KRAS) in a bone metastasis site that was not
detected in the cfDNA. In P8, a focal amplification in 19p (1.52 mb) was not detected in
the matched seminal vesicle metastasis, while in P9, a focal amplification in 11p
(6.7 mb) was not detected in the corresponding adrenal gland metastasis. Similarly,
P12 had amplifications in 8q (MYC) and Xp (AR), while P13 had two focal
amplifications in Xp (AR and ELK1), which were not detected in the matched metastatic
tissues (Fig. 8f).
Analysis of the MAFs showed a linear correlation for most somatic mutations,
but also identified mutations that were exclusive to either the plasma DNA or the
metastatic sites (Fig. 7d–f, Fig. 8a-f). However, most driver mutations
including TP53, AR, ATM, SPOP, FLI1, and OR5A1 were detected in both the plasma
DNA and tissues. Overall, the matched tissue data showed a high concordance in
CNAs and point mutations between cfDNA and metastatic tissues, suggesting that the
ctDNA is highly representative of many of the genomic aberrations detected in tumor
tissues.
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Fig. 8: Concordance of cfDNA and metastatic tissue samples in additional patients
(a-f) Genomic copy number data and exome mutations for 6 additional PC patients with
matched metastatic tissue samples, with prostate cancer genes labeled.

Genomic response to therapy in plasma DNA
We next applied PEGASUS to plasma DNA samples collected serially (2–6 timepoints)
from 12 patients, including 9 CRPC patients (P8, P9, P10, P14, P15, P16, P17, P21)
and 3 CSPC patients (P6, P19, P20), to study genomic response to therapy (Table 2).
The 3 CSPC patients were treated with ADT and a tyrosine kinase inhibitor
(cabozantinib), while the CRPC patients received different chemotherapeutic and
androgen-targeted agents (Fig. 9, Table S). From each timepoint, genomic CNA
Table S2 – Clinical
informationsequencing
on the profiled prostate
cancer
patients.125X)
Clinical information
and treatments administered
the metastatic
profiling
and exome
(mean
depth
were performed
on the tocfDNA,
as
CSPC and CRPC patients that were analyzed using PEGASUS in this study. Columns listed include clinical parameters for: (1) the patient
identifier, (2) date of first plasma sample collection analyzed (3) classification of castration-sensitive or resistant disease at the data of sample
collection, (4) patient age, (5) prostate specific antigen levels (ng/mL), (6) Gleason Score, (7) site of metastatic tumors, (8) progression-free
survival in days, (9) overall survival in days, (10) treatments received starting at the date of the first plasma sample collection, and (11) prior
treatment received by the patient before the first plasma sample collection.

well as matched normal PBMC samples (mean depth 77X) to detect germline variants.

patient
P1
P2
P3
P4
P5
P6
P7
P8
P9

date
9/2/15
4/25/14
12/18/13
05/23/16
7/15/13
10/22/13
2/16/15
10/24/13
4/14/16

prostate
cancer
subtype
CRPC
CRPC
CRPC
CRPC
CRPC
CSPC
CRPC
CRPC
CRPC

age
61
64
63
74
72
61
75
69
67

PSA
0.4
1.5
5
234.8
146.5
491.5
91.9
6.8
39.6

GS
9 (4+5)
9 (4+5)
9 (4+5)
9 (4+5)
9 (4+5)
9 (4+5)
9 (4+5)
9 (4+5)
9 (4+5)

P10
P11

3/28/16
5/16/16

CRPC
CRPC

55
67

154.8
231.8

P12
P13
P14
P15
P16
P17
P18
P19
P20
P21
P22
P23

5/23/16
10/14/16
2/27/14
4/15/14
5/19/14
1/20/15
10/17/14
8/6/14
6/12/15
7/7/16
01/05/16
06/17/16

CRPC
CRPC
CRPC
CRPC
CRPC
CRPC
CRPC
CSPC
CSPC
CRPC
CSPC
CRPC

69
68
59
73
77
59
73
62
75
67
60
61

31.7
349.3
5603.4
79.7
72.6
27.7
6
12.9
1.9
1.6
234.9
171.1

PFS
(days)
171
276
42
87
299
161
186
133
50

OS
(days)
262
828
207
189
742
1061
243
522
205

8 (4+4) Lymph Nodes, Bones
10 (5+5) None

68
289

141
NR

8 (4+4)
7 (4+3)
NA
7 (3+4)
6 (3+3)

75
60
102
302
136
84
208
171
180
213
150
277

106
90
561
509
519
269
694
533
883
NR
484
575

8 (4+4)

9 (4+5)
9 (5+4)
9 (5+4)
9 (4+5)
9 (4+5)
9 (5+4)

Metastatic Sites
Lymph Nodes, Bones
Lymph Nodes
Bones, Liver
Lymph Nodes, Bones, Lung
Bones
Lymph Nodes, Bones
Lymph Nodes, Bones
Lymph Nodes, Bones
Lymph Nodes, Bones, Adrenal

Bones, Liver
Lymph Nodes, Bones
Lymph Nodes, Bones, Lung
Lymph Nodes, Bones
Lymph Nodes, Bones
Lymph Nodes, Bones,Liver
Bones, Adrenal Gland
Lymph Nodes, Bones
Bones
Lymph Nodes, Bones
Lymph Nodes, Bones
Bones, Lung, Liver

on-study treatment
Docetaxel + Carboplatin
Cabazitaxel
Cabazitaxel
Docetaxel + Carboplatin
Cabazitaxel+Carboplatin
ADT
Cabazitaxel+Carboplatin
Cabazitaxel
Docetaxel
Cabazitaxel +
Carboplatin +
Abiraterone
ADT

previous treatments
Abiraterone+Enzalutamide, Cabazitaxel+Carboplatin
ADT, Radiation
Radiation ,Bicalutamide, Abiraterone+Enzalutamide
Cabazitaxel+Carboplatin, Radiation, CVD
Bicalutadmide, Nilut, Abiraterone
Naïve
ADT, Bicalutamide
Bicalutamid, Abiraterone, Dasatinib, Sunitinib
ADT, Abiraterone+Sunitinib

ADT+Cabozantinib, Docetaxel+Carboplatin,
Cabazitaxel+Carboplatin
Naïve
Radiation, Radium223, Docetaxel+Carboplatin,
Enzalutamide, CVD, Abiraterone, Cabazitaxel,
Carboplatin + Etoposide Docetaxel
Cyclophosphamide
bicalutamide, Enzalutamide, XRT
ADT
Naïve
Cabazitaxel
Bicalutamide, Enzalutamide
Cabazitaxel
Bicalutamide
Cabazitaxel+Carboplatin ADT, Enzalutamide
Cabazitaxel
ADT, Bicalutamide, Abiiraterone+Enzalutamide
ADT + Cabozanitib
Naïve (T<20)
ADT + Cabozantinib
Naïve (3 mos on ADT)
Docetaxel + Carboplatin Bicalutamide
ADT
naïve
Cabazitaxel+Carboplatin Docetaxel, Sipuleucel-T, Enzalutamide, Abiraterone

Table 2: Clinical information on the profiled prostate cancer patients.
Clinical information and treatments administered to the metastatic CSPC and CRPC
patients that were analyzed using PEGASUS in this study. Columns listed include
clinical parameters for: (1) the patient identifier, (2) date of first plasma sample
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collection analyzed (3) classification of castration-sensitive or resistant disease at the
data of sample collection, (4) patient age, (5) prostate specific antigen levels (ng/mL),
(6) Gleason Score, (7) site of metastatic tumors, (8) progression-free survival in days,
(9) overall survival in days, (10) treatments received starting at the date of the first
plasma sample collection, and (11) prior treatment received by the patient before the
first plasma sample collection.
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Fig. 9: Genomic response in longitudinal cfDNA samples
a Total number of CNAs detected in longitudinal timepoints from 12
patients. b Mutation burden quantified from exome data of 12 patients, using all exonic
mutations. c–h Plots of treatment schedules and therapeutic agents against changes in
PSA levels (ng/mL) in 6 patients, with genomic copy number heatmaps and exome
MAF plotted below for each timepoint. c, d CSPC patients with increasing mutations
and CNAs. e, f CRPC patients with minor changes in mutations in CNAs during
treatment. g, h CRPC patients with transient genomic response. Colors in mutation line
plots represent different clones inferred by CITUP (the “Methods” section), while blue
colors in PSA plots represent timepoints that were sampled for sequencing analysis.

On average, 126 somatic mutations (Fig. 9a) and 21 CNAs (Fig. 9b) were
detected per patient, consistent with previously reported values in advanced prostate
tumors [85, 94, 96, 97]. Integrated analysis revealed that the CNA burden (Fig. 9a) and
point mutation burden (Fig. 9b) did not change substantially between the pre-treatment
and post-treatment timepoints for most CRPC patients. However, in the mid-treatment
timepoints, the CNA burden and mutation burden decreased substantially in several
patients (P15, P16, P21), suggesting a transient genomic response to therapy. Notably,
two CRPC patients (P10, P18) had high levels of somatic mutations (mean 601.5
SNVs), consistent with a hypermutator genotype [94, 95].
To investigate genomic response to therapy, we compared the plasma CNA
profiles and exome

34

MAF with the PSA levels for each patient (Fig. 9c–h, Fig. 10a-f).
Fig. 10: Genomic Response in Longitudinal cfDNA Samples from Additional Patients.
(a-f) Plots of treatment schedules and therapeutic agents against changes in PSA
levels (ng/mL) in 6 additional PC patients, with genomic copy number heatmaps and
exome MAF plotted below for each time point. Colors in mutation line plots represent
different clones inferred by CITUP (methods), while blue colors in PSA plots represent
time points that were sampled for sequencing analysis.
In 2 CSPC patients (P19 and P20), we found increasing numbers of CNAs and
mutations during treatment that corresponded to increasing PSA levels. In P6, who was
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hormone-naïve at the time of his first blood collection, an aneuploid profile was
detected at both timepoints and accumulated CNAs at T2 as the disease progressed to
CRPC. A comparable increase in mutation burden over time was found in one CRPC
patient (P18) receiving chemotherapy (Fig. 10d). In these patients, the increase in
genomic aberrations over time was likely due to increasing tumor purity due to
increasing tumor volume and/or increasing tumor DNA shedding, rather than
acquisition of new CNAs in response to treatment, since the total number of
chromosome breakpoints did not change over timepoints.
In the 9 CRPC patients, complex aneuploid rearrangements and high MAF were
detected at the baseline plasma sample (prior to treatment) and at the mid- or posttreatment timepoints. In P9, P10, P14, and P17, the complex aneuploid
rearrangements and MAF were pre-existing before therapy and persisted through all of
the timepoints analyzed, suggesting the tumors were intrinsically resistant to the
therapies administered (Fig. 9e–f, Fig. 10c-d). In contrast, P15, P16, and P21 showed
transient genomic responses to therapy in the mid-treatment timepoints, in which the
genomic CNA profiles approached a near-diploid state and the MAF decreased
substantially (Fig. 9g-h, Fig. 10e). However, these responses were temporary, and the
complex CNA profiles and high MAF returned in the later timepoints which is consistent
with the change in PSA values.
In most patients, all of the CNAs were detected at the pre-treatment timepoint
and did not change during treatment, suggesting the CNA had been acquired at earlier
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stages of tumor progression, prior to treatment (Fig. 11).

Fig. 11: Clonal evolution in response to treatment inferred from cfDNA.
Plots of clonal lineages and frequency changes over time and in response to treatment
for 12 patients. CNAs and mutations are labeled in the inferred lineages, as well as
significant mutations identified in the resistant clones (blue, asterisk) on the right-hand
side. a Patients in which subclones were identified that expanded in response to
therapy. b Patients in which clonal frequencies were persistent and remained stable
during treatment
This included amplifications in AR (10/12 patients), MYC (7/12 patients),
and NCOA2 (7/12 patients) and deletions in PTEN (5/12 patients), RB1 (3/12),
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and BRCA2 (3/12) (Fig. 9, Fig. 10). The only exception was in P6 who acquired
an AR amplification in response to ADT (Fig. 10a).
In contrast to the CNAs, many mutations underwent dynamic changes in MAFs
in response to therapy and the rise or drop of MAFs was fairly consistent with the rise
or drop in PSA levels. In the CSPC patients, the MAFs increased (P19, P20) or
remained stable (P6) during treatment timepoints. In the CRPC patients, the MAFs
persisted with only minor frequency changes in patients with intrinsically resistant
disease (e.g., P14, P17) or showed transient decreases in patients that were
responding to therapy (e.g., P15, P16). This included point mutations in known PC
driver genes, including TP53 (P6, P9, P10), AR (P10), SCN11A (P16), NCOA2 (P19),
and other genes (Fig. 9, Fig. 10). We also identified sub-clonal mutations that emerged
during treatment, including mutations in PTEN (P21), RNF43, PIK3R1 and ZNRF3
(P15), SPOP, RUNX1 and AR (P10) and CTNBB1 (P17). Many other somatic
mutations were detected in genes not associated with PC, and increased or decreased
in MAFs during treatment, suggesting a potential association with sensitivity or
response to the therapeutic agents.

Clonal evolution in response to therapy
To infer clonal evolution and identify subclones associated with resistance, we
integrated the genomic CNA and exome mutation data from the serially collected
plasma samples of the 12 patients. The confounding effects of tumor purity on CNA
and MAF were normalized, and subclones were inferred across multiple timepoint
samples using PyClone2 [25] and CITUP [29] (the “Methods” section, Fig. 12). We
identified multiple subclones (range 2–8) in the 12 patients and identified dynamic
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changes in clonal frequencies in response to therapy (Fig. 11). In 9 patients, minor
subclones (1–21%) were identified

Fig. 12: Purity and Copy Number Normalization of MAF in Longitudinal cfDNA Data
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(a-l) Left panels showing raw exome MAF prior to purity correction and copy number
normalization compared to right panels showing the inferred clonal frequencies after
normalization for the 12 prostate cancer patients

that expanded in response to therapy (Fig. 11a), while in 3 patients (P6, P21, and P17),
the most prevalent clone retained a similar frequency during treatment, suggesting that
the dominant clone was intrinsically resistant to the treatment (Fig. 11b).
The clonal frequency data identified rare subclones that dynamically expanded during
therapy and were therefore associated with resistance (Fig. 11a). For example, in P20,
a minor subclone (clone G) with 7–11% clonal frequency in the initial timepoints (T1–
T3) expanded to 75% at the final treatment timepoint (T4). This subclone harbored
significant damaging mutations (SIFT< 0.05, POLYPHEN > 0.85) in two
genes: CAPN2 and MRPL47. In P18, a rare subclone (clone G) expanded from 6% at
T3 to 53% at T4 and harbored three significant mutations: SLC18A3, TNIK,
and OR2AE1. In P16, a rare subclone (clone G) expanded from 3 to 4% at the initial
timepoints (T1–T2) to 41–57% at the final timepoints (T4–T5) and harbored significant
mutations in EIF3G and MRPL2. In total, 9 patients were identified in which a minor
subclone expanded during treatment, suggesting association with resistance.
The resistant subclones harbored a total of 36 mutations with significant SIFT (< 0.05)
and POLYPHEN (> 0.85) functional impact scores (Table 3). Notably, this data did not
identify any recurrent genes associated with resistance; however, several recurrent
gene families were identified, such as the solute carrier transporters
(SLC12A3, SLC38A7, SLC18A3, and SLC26A2) and the mitochondrial ribosomal
protein genes (MRPL2 and MRPL47). Despite the lack of recurrence, many of the
genes identified in the resistant clones have been previously implicated in PC
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progression or therapeutic resistance. For example, NCAPG detected in P15 is part of
the condensin complex and has been related to CRPC pathogenesis [98,
99]. LGALS3 detected in P8 is a member of the galectin proteins involved in apoptosis,
immunity, and adhesion, and was linked to treatment resistance in PC [100,
101]. CAPN2 detected in P20 is an intracellular cysteine protease and has been shown
to promote cell proliferation and invasion in CRPC cell lines [102].
Furthermore, WWC1, which was identified in P14, was found to be upregulated in
antiandrogen-resistant PC cell lines [103].

Table 3: Mutations in Resistance-Associated Clones that Expanded in Response to
Therapy.

Mutations in Resistance-Associated Clones that Expanded in Response to Therapy.
List of the significant mutations with SIFT (S< 0.05) and Polyphen (P> 0.85) scores in
the resistant clones that expanded in response to therapy in 9 of the prostate cancer
patients with serial data. The columns listed include: (1) patient identifier, (2) inferred
CITUP clone number (3) gene names, (4) reference nucleotide variant, (5) mutant
nucleotide variant, (6) chromosome number, (7) chromosome position, (8) Polyphen2
significance score, (9) SIFT score, (10) mutation type, including nonsynonymous (NSN)
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or stop gain (STOP), (11-15) raw variant allele frequencies of the somatic mutations in
the plasma at different time points (16) GenBank identifier, (17) short description of the
gene function, (18) Overall survival p-value for genes in TCGA datasets, (19)
Benjamini-hochberg adjusted p-values for genes in TCGA datasets.
We further investigated if the resistance-associated mutations identified in this
study were correlated with poor survival in the TCGA datasets (N = 3811 patients), and
found significant associations with poor survival for CAPN2, CHDR2, LGALS3, L1CAM,
MORC1, EIF3G, OR8A1, TNIK and SMYD3 (adjusted p value < 0.05, BenjaminiHochberg correction) (Table 3, the “Methods” section). Collectively, these data suggest
that the evolutionary analysis of clonal dynamics in cfDNA may be useful for delineating
intratumor heterogeneity and identifying resistant clones and mutations associated with
therapy response and resistance in prostate cancer patients.
Discussion
Here, we report the development of an unbiased whole-genome sequencing
approach for cryostored plasma DNA and its application to study clonal diversity and
evolution in response to therapy in PC patients. In contrast to targeted cfDNA methods
[86, 104], PEGASUS was designed to perform unbiased genome-wide profiling of
CNAs and mutations, which are necessary to infer evolutionary dynamics over time and
identify clones associated with response to therapy.
In several patients, we compared plasma DNA directly to matched tissue
samples from metastatic organ sites. Our findings suggest that the genomic aberrations
identified in cfDNA are highly representative of the metastatic tissue sites, but also that
the cfDNA also contains mutations that are not present in the matched metastatic
tissues. These additional mutations in the plasma may originate from other metastatic
foci or micro metastases that were not profiled in this study. Based on this data, we
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speculate that cfDNA provides a more holistic representation of a patient’s cancer
genomic aberrations, across many of the primary and metastatic tumor sites, compared
to core biopsy samples that reflect a limited spatial area in a single tissue site.
We further applied PEGASUS to analyze serial plasma samples collected from PC
patients that received different combinations of hormonal and chemotherapy
treatments. Our data showed that complex aneuploid rearrangements remained highly
stable during treatment, with few or no new CNA acquired during this time. This data
suggest that CNAs are likely to have occurred early in tumor evolution and may be
related to intrinsic (rather than acquired) resistance of the tumor cells. In contrast, the
MAF in the cfDNA underwent dynamic changes in response to treatments. In most
patients, clones present in low frequency in the pre-treatment timepoints expanded
during therapy and harbored mutations associated with resistance. Many of the
genomic aberrations in the genes identified (N = 9) in the resistance clones were
correlated with poor survival in larger cohorts of PC patients in TCGA. However, most
mutations identified in the resistant clones were not recurrent across patients, a
possible reflection of the heterogeneous nature of the treatments or alternatively of
diverse mechanisms of resistance. An exception was several recurrent mutations in
solute carrier transporter genes (SLC) and mitochondrial ribosomal protein (MRP) gene
families. The SLC genes are of considerable interest from a therapeutic standpoint,
since they are involved in the uptake and transport of drugs into cells and therapeutic
resistance [105]. Future studies will be needed to functionally validate these mutations
and understand their potential role in therapy resistance in PC patients.
Several clinical parameters identified correlated with increased plasma cfDNA
concentrations, including the presence of aneuploid genomes, increased disease
volume, accelerated progression, and poor OS. For cancers progressing in sites that
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are difficult to biopsy and/or that are unlikely to yield enough tumor cells to allow for
genomic analysis (e.g., bone), PEGASUS may provide an invaluable profiling tool to
discover genomic biomarkers associated with disease behavior and drug sensitivity.
Global genomic features such mutation burden measured in the cfDNA may have
clinical utility for identifying patients with increased neoantigens that are ideal for
treatment with immune checkpoint inhibitors. Furthermore, the CNA burden or
aneuploid aberrations detected in cfDNA may be used to detect tumors
with homologous recombination deficiency (HRD) in patients who may benefit from
agents targeting DNA damage repair defects such as PARP inhibitors [106, 107].
Indeed, our data suggest that the detection of aneuploid copy number profiles in
plasma DNA is an indicator of poor survival in PC patients, as are higher
concentrations of cfDNA in the blood.
The use of PEGASUS to study genomic aberrations in plasma DNA has a few
limitations. Foremost, because the genomic profiling is unbiased and broad by the
assay design, it requires significant sequencing coverage (e.g., 150X) and higher cost,
compared to targeted panels, which also have a higher sensitivity for detection of rare
mutations. Another limitation is that the approach is more suitable for patients with
advanced and metastatic disease and is unlikely to have utility in the detection of early
disease, where the concentration of ctDNA in the plasma is very low. This was an issue
in the initial timepoints analyzed in the CSPC patients, where only diploid genomes
were detected prior to progression to CRPC disease. In such cases, the use of targeted
plasma DNA sequencing panels (e.g., Guardant360, Oncomine) would be more
appropriate to increase detection sensitivity.
In closing, we expect that PEGASUS will have a myriad of applications in cancer
research, particularly in the discovery and identification of genomic mechanisms of
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response and resistance to anticancer therapy in large patient cohorts, where
longitudinal plasma samples have previously been collected and cryostored for
achieving purposes and long-term clinical outcome data is available. Our approach will
be particularly useful in the non-invasive genomic profiling of solid tumor tissues that
are challenging to biopsy (e.g., kidney, brain, lung, bone). We expect that these
longitudinal genomic analyses will reveal basic mechanisms of response and disease
resistance and may lead to new clinical assays that can monitor response to
therapeutic agents and guide treatment decisions in cancer patients.
Conclusions
This study shows that unbiased whole-genome sequencing of plasma DNA from
prostate cancer patients can detect mutations and copy number alterations that can be
used to infer clonal dynamics and genome evolution longitudinally in response to
treatment. By computationally integrating this data over multiple timepoints, we use an
evolutionary approach to identify clones that harbor mutations associated with
therapeutic resistance.
Methods
Patient clinical data and sample information
All patients in this study were treated for prostate cancer at the University of
Texas MD Anderson Cancer Center (Houston, TX) and provided informed consent per
an Institutional Review Board-approved prospective protocol. Two patient cohorts were
included: (i) newly diagnosed metastatic and hormone-naïve (CSPC) (including
patients participating in clinical trials NCT01409200 or NCT01630590) and (ii) CRPC
(including patients participating in clinical trial NCT01505868). All blood plasma and
tissue samples were collected before initiation of systemic treatment, while progressing
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on therapy by PSA or radiologic criteria, or while on systemic treatment as indicated.
Patients were prospectively followed from the time of inclusion until the last visit or
death. Matched metastatic tissue samples were obtained as FFPE blocks from the
respective patients. Patients were classified as aneuploid or diploid based on the
whole-genome copy number data from the plasma. Patients with worsening
performance status, pain, or other symptoms related to tumor growth in the 6 weeks
prior to the blood specimen collection, and/or with development of > 2 new metastatic
lesions in a single site or new non-nodal organ site extension in the previous 3 months,
were classified as “accelerated progressors”; all other patients were defined as
“protracted progressors.” Patients were classified as “high disease volume” if they had
> 10 focal bone metastases or equivalent and/or tumor mass > 4 cm at any site, and/or
extension to at least three organ sites with one lesion at least 2 cm in diameter; “low
disease volume” if patients had ≤ 4 bone metastases with or without extension to lymph
nodes up to 2 cm in diameter; all others were categorized as “intermediate disease
volume” patients. A sample was classified as aneuploid if the CNA profile contained a
large number of segments (> 45) and had a deviation from the median segmentation
value (> 0.03) that was not explained by technical noise. If the sample had an
intermediate number of segments (between 25 and 45), it was considered aneuploid if
it had a deviation from the median segmentation value (> 0.03) and a large segment
size or high segmentation value. All other samples were classified as diploid.
Isolation of plasma DNA from blood plasma and quality control
Blood (approximately 7.5 mL) from the prostate cancer patients was collected in
Ficoll tubes (catalog no. 362753). After gentle inversion, tubes were centrifuged at
1800g for 15 min at room temperature. The plasma layer was separated from the
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nucleated PBMC cell layer and centrifuged three times at 1500g for 10 min to
remove contaminating cells. The PBMC layer was used to isolate genomic DNA, which
was sequenced separately to identify germline variants (see genomic DNA isolation
and quality control section). In cases where fresh blood samples were not available,
frozen plasma stocks stored at − 80 C were thawed and centrifuged at 16,000g three
times to remove all cryoprecipitates. Low molecular weight plasma DNA was purified by
size selection (< 1000 bp) from high molecular weight DNA using the QIAamp®
Circulating Nucleic Acid Kit (QIAGEN Cat. no. 55114) according to the manufacturer’s
instructions. Final carrier RNA concentration of 1.3 ng/μL was used to improve yields.
For quality control, plasma DNA fragment size and concentrations were measured
using high sensitivity (HS) Bioanalyzer chips or TapeStation HS D1000 tape cartridges.
The plasma DNA concentration and size range that was measured for QC was gated
on fragments within the 100–700-bp range to exclude contaminating high molecular
weight genomic DNA when present.
DNA isolation and sequencing of tissue samples
PBMC layer or plasma pellets were utilized to extract the reference genomic
DNA using QIAGEN Kits (Cat. no. 51106 and 56304, respectively) according to the
manufacturer’s instructions. FFPE DNA from metastatic tissues was isolated using the
QIAamp DNA FFPE Tissue Kit (QIAGEN Cat. no. 56404) following the manufacturer’s
instructions.
The isolated DNA quality was assayed through agarose gel electrophoresis or
TapeStation genomic DNA tapes to determine size and concentration. The resulting
gDNA was used to construct low-input DNA sequencing libraries with the Hyper Prep
kit (Kapa Biosciences cat. no. KK8504) according to the manufacturer’s instructions.
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Genomic DNA from PBMCs was sonicated to 200 bp (Covaris Peak power 175,
Duty Factor 10%, cycles/burst 200, time 180 s, temp 4–7 °C) prior to end repair and atailing steps. Post-ligation cleanup was performed with 0.8X AMPure XP beads. PCR
amplification of plasma DNA samples was performed at 11 PCR cycles. Final
sequencing libraries were split into two pools for either copy number sparse WGS or
exome capture. The copy number libraries were sequenced at 36 or 76 cycles singleend on the Illumina HiSeq4000 system. The exome libraries were further captured
using the SeqCap EZ Exome V2 kit following the manufacturer’s instructions
(Nimblegen-Roche Cat. no. 05860482001). The final exome libraries were sequenced
at 76 or 100 paired-end reads on the Illumina HiSeq4000 system.
Plasma DNA library construction and exome sequencing
The plasma DNA that passed QC by having ≥ 2 ng total DNA and size
distributions < 1000 bp were used to construct low-input DNA sequencing libraries with
the Hyper Prep kit (Kapa Biosciences cat. no. KK8504) according to the manufacturer’s
instructions. Post-ligation cleanup was performed with 0.8X AMPure XP beads. PCR
amplification of plasma DNA samples was performed at 11 PCR cycles. Final
sequencing libraries were split into two pools for either copy number sparse WGS or
exome capture. The copy number libraries were sequenced directly at 36 or 76 cycles
single-end on the Illumina HiSeq 4000 system. The exome libraries were captured
using the SeqCap EZ Exome V2 kit following the manufacturer’s instructions
(Nimblegen-Roche Cat. no. 05860482001). The final exome libraries were sequenced
at 76 or 100 paired-end reads on the Illumina HiSeq4000 system.
Analysis of genomic copy number data using circular binary segmentation (CBS) from
plasma DNA and tissues

48

Reads sequenced were demultiplexed using the “bcltofastq” software (Illumina)
and split into individual FASTQ files, allowing a 1 basepair mismatch for barcode edit
distance. Copy number profiles were detected from read depth counting of the
sequencing data using the “variable binning” pipeline as previously described [14]. This
pipeline involved mapping FASTQ files to the human genome assembly NCBI Build 37
(hg19/NCBI37) using Bowtie2 (2.1.0) alignment software [108]. The aligned reads in
SAM files were converted to BAM files and sorted using SAMtools (0.1.16) [109]. PCR
duplicates were marked and removed using Picard in GATK [110]. The reads were
counted using variable bin sizes at an average genomic resolution of 220 kb. Unique
normalized read counts were segmented using the CBS [111] method from R
Bioconductor “DNAcopy” package followed by MergeLevels [112] to join adjacent
segments with non-significant differences in segmented ratios. The parameters used
for CBS segmentation were alpha = 0.0001 and undo.prune = 0.05. Default parameters
were used for MergeLevels, which removed erroneous chromosome breakpoints.
Finally, we used ggplot packages in R to plot the segmentation and log2(ratio) values
and annotate prostate cancer genes in regions of amplification and deletion. The
prostate cancer gene list of 100 genes was compiled from two published papers [96,
113].
Calculation of CNA lengths and correlation between plasma and metastatic samples
The neutral copy number state was defined as the median segmentation ratio of
all genomic bins. Any group of consecutive bins with the same segmentation ratio not
equal to the copy neutral state within a chromosome was defined as a CNA. The CNA
length was defined as a difference between the bin start position and bin end position.
Every CNA contained a list of bins with the same segmentation ratio values. These
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segmentation values from the plasma and metastatic samples were used to calculate
the correlation values using the Pearson correlation coefficient.
Detection of mutations in plasma exome sequencing data
The plasma DNA data from each patient was aligned to the human genome
reference assembly (hg19) using Bowtie2 (2.1.0) [108] and converted into a binary
format (BAM) with Samtools [109]. The SAM file was sorted using samtools, and PCR
duplicates were marked using Picard tools [114]. Genome Analysis Toolkit [110]
(GATK)’s BaseRecalibrator and PrintReads were used to obtain BAM files that have
been recalibrated for base quality scores. Somatic variants were identified using the
plasma and matched PBMC samples using GATK’s MuTect2 [115] to generate a
variant call format (VCF) file. The filtering functionality of the MuTect2 VCF file was
enabled using GATK’s FilterMutectCalls, and the somatic variants classified as “PASS”
(high confidence) and “germline risk” (borderline somatic) were retained. The filtered
somatic variants were split into single nucleotide variants (SNVs) and indels using
GATK’s SelectVariants function. The chromosome number and position of the variants
were extracted, and samtools was used to obtain the read counts across all the variant
sites. Variants with less than 0.07 variant allele frequency in the plasma sample were
removed from analysis. Additionally, variants were removed from analysis if they had
more than 2 variant reads in the PBMC samples sequenced at less than 100X depth or
more than 0.01 variant allele frequency for samples sequenced at greater than 100X
depth. These read depth filters remove the mutect2 “germline risk” calls that are like to
be germline mutations and are not somatic mutations. The resulting data was
annotated using ANNOVAR [116] by integrating multiple databases, including dbSNP,
COSMIC [117], and the Cancer Gene Census [118]. To identify mutations and copy
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number variations (CNV) in genes of interest, an exon coordinate file was intersected
with BedTools [119]. The functional significance of each SNV was predicted using SIFT
[120] and POLYPHEN [121]. Mutations with < 0.05 SIFT scores and > 0.85 POLYPHEN
scores were considered significant for impacting gene function.
Identification of concordant mutations in matched metastases
The total number of CNAs per sample was estimated above a baseline threshold
for amplifications and deletions in each patient. The CNA correlation between the two
sample sources was calculated using the Pearson correlation coefficient of the
segmentation means, while the mutational concordance was calculated as the
percentage of the ratio between the concordant mutations and the total number of
mutations in the plasma and tissue sample combined.
Survival analysis by plasma DNA concentration
We utilized survival data from 140 baseline CRPC plasma samples who were
part of trial NCT01505868 for survival analysis. The samples were categorized into 2
groups based on total cfDNA (> 2 ng or < 2 ng) to prepare libraries. The overall and
progression-free survival months and the group information were used for survival
analysis using the Kaplan-Meier estimator using the “survminer” library in R (3.5.0).
The p value of the log-rank test was calculated, and the two groups were considered
significantly different if the p value was p < 0.05.
Estimating clonal frequencies from mutation data
Non-synonymous and synonymous somatic mutations were identified in the
plasma samples for 12 PC patients with 2 to 6 longitudinal samples. The plasma DNA
genomic copy number profiles were estimated from the paired-end exome sequencing
depth using the R package “ExomeCNV” [122]. For ExomeCNV analysis, the minimum
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sensitivity and specificity was set to 0.9999 while it was optimized using the AUC
criteria. Tumor purity was estimated with THetA2 [123] using the tumor and normal
GATK recalibrated bam files while the minimum fraction of the genome with a potential
copy number event for the sample was set to 0. The variant allele frequencies from
each point mutation were normalized with both exome-derived copy number profiles
and estimated tumor purities using PyClone2 (v0.12.9) [25]. The copy number and
purity-adjusted clonal frequencies were then used as input for CITUP [29] for the joint
calculation and estimation of clonal subpopulations using the optimal trees across the
longitudinal timepoints from same patient. Finally, the clonal lineages were plotted with
“timescape” [124] using the CITUP tree structures and the clonal frequencies across
the longitudinal timepoints for individual PC patients.
Survival analysis of resistant genes from TCGA
Selected prostate cancer studies [125-139] including the prostate cancer (MSK,
2019), prostate adenocarcinoma (TCGA, provisional), and The Metastatic Prostate
Cancer Project that were available on cBioPortal (www.cbioportal.org) were used for
survival analysis to determine if genomic aberrations in significant genes associated
with resistance were associated with poor patient survival in the expanded patient
cohorts. All the genes reported in Table 3 are tested, and p values from log-rank test
were calculated. The p values from the log-rank test were then adjusted using the
Benjamini-Hochberg procedure.
Cox regression model for OS and PFS using available clinical and genomic parameters
Using data from 70 prostate cancer patients with available clinical data across all
clinical and genomic parameters, we performed a Cox regression model using the
“survival” R package. We used the coxph function by utilizing one or all the factors as

52

predictors and the survival months as the outcome variable for the univariate or
multivariate analysis. Any predictor that had a p value < 0.05 was considered
statistically significant. For the discrete clinical and genomic parameters, total cfDNA
< 2 ng, diploid cfDNA profiles, low disease volume, protracted rate of progression, and
prostate disease were used as a reference for the Cox regression models.
3. PLASMA GENOME SEQUENCING IDENTIFIES GENOMIC EVOLUTIONARY
CLASSES IN RESPONSE TO PROSTATE CANCER TREATMENT
Background
Prostate Cancer (PC) is generally an indolent disease but once it becomes
resistant to Androgen Deprivation Therapy (ADT), the patient survival reduces
dramatically [140]. PC is known to be a heterogeneous disease with multiple distinct
alterations such as PTEN, TP53 and RB1 contributing to the disease progression [113,
141]. Despite significant advances in understanding PC ITH, better classification
methods are necessary to improve prognostic accuracy and therapeutic outcomes
[142]. The presence of extensive bone disease, a common metastatic site in metastatic
PC (mPC), makes it challenging to study and evaluate the disease. A limitation unique
to mPC is that measurements such as Response Evaluation Criteria in Solid Tumors
(RECIST) criteria, that are utilized in cancers to quantify response and resistance do
not work effectively due to extensive bone metastasis. These sites do not have a
regular shape, therefore, the tumor size cannot be measured easily and are frequently
considered unmeasurable [143]. Therefore, the patient classification is generally based
on factors such as PSA changes, metastasis and disease stage [142]. In addition to
clinical features, genomic data from one primary PC foci per patient in the TCGA study
has been used to determine molecular classes. These classes were based on the ETS
transcription factor genes (ETV1, ETV4, FLI1 and ERG) and point mutations in SPOP,
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FOXA1 and IDH1. Unfortunately, the correlations between clinical data and these
classes were not significant possibly due to the extent of heterogeneity between foci in
PC [141].
In the previous study described in chapter 3, we developed PEGASUS to utilize
blood samples to illustrate that archival plasma samples can be utilized to profile CNAs
and point mutations from archival plasma samples [144]. The data obtained from this
approach provides a large number of markers without prior knowledge of the tumor.
Additionally, a large number of longitudinal samples can be profiled because of the
significant ease of blood collection compared to invasive prostate or bone biopsies.
Studies have shown that plasma DNA often detects mutations that not observed in the
tissue sample [56, 145, 146]. These studies are of significance in the PC domain
because the plasma may account for heterogeneity between metastatic sites as well as
between multiple PC foci and may improve the patient classification.
In this study, we profiled longitudinal plasma samples from mPC patients to
investigate the extent of ITH in the plasma. Furthermore, we investigate whether the
longitudinal CNA and point mutation data can classify the mPC patients into clinically
relevant subgroups.
Results
mPC patients treated with hormone ± chemotherapy
This study is focused on 78 PC patients with metastatic disease treated with
hormone and/or chemotherapy. These patients had a diverse history of treatments but
the longitudinal samples collected for this study were treated with ADT, abiraterone
based, cabazitaxel ± carboplatin, docetaxel and radium-223 therapies. Each of these
patients had 2-10 blood samples collected pre-treatment, on-treatment and posttreatment. The 379 longitudinal blood/plasma samples collected from 78 mPC patients
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were subject to the PEGASUS protocol as described in the previous chapter to obtain
whole-genome copy number data. Longitudinal samples from 60 mPC patients had
atleast 1 aneuploid (CNA) time point and were subject to exome sequencing.
Estimating integer copy numbers from whole-genome profiling of longitudinal plasma
DNA
The segmentation ratios obtained from the CBS CNA pipeline (methods) is
centered around the mean ploidy. We utilized the power of longitudinal samples to
estimate of ploidy, purity and thereby, obtain estimates of integer copy number
(methods). This is in contrast to chapter 3 where the exome data was used to call
integer copy number. For the time points with low tumor purity, integer copy number
estimation was done using ploidy of 2 and purity of 0 which sets the entire CN profile to
a diploid sample. This ploidy and purity assumption were made because correction
using very low purities amplifies the noise and makes the integer estimates inaccurate.
Fig. 13 shows 4 examples of patients where the integer copy numbers were calculated
by utilizing ploidy consistent across all aneuploid time points as determined by
ichorCNA (methods) [47]. These plots indicate that the majority of CNAs are consistent
across all the aneuploid time points. However, a few regions show variation between
timepoints. For example, we detected a region on chromosome 8 in patient PR6 (Fig.
13a), that fluctuated between CN state 5 and 6. Another example can be illustrated by
data from patient PR17 (Fig. 13b), where CN variation was detected in chromosomes 8
and 17. Taken together, the consistent CNAs across the aneuploid time points
suggests that the integer copy numbers are likely to be biologically meaningful
solutions.
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Fig. 13: integer copy number estimates from longitudinal plasma DNA samples
The colors in the heatmap represent the integer copy number states.

Single time point analysis at the time of maximum tumor mutation burden
To evaluate ITH in our mPC cohort, we selected a time point from every patient
using the highest tumor mutation burden. We utilized this time point from every patient
to evaluate CNAs and SNVs for a consensus gene list containing genes collected from
previous mPC studies [127, 136] as well as the top 25 mutated genes in our cohort.
Among the 60 mPC patients with CNA and exome data, 11 patients were dropped from
our analysis because of insufficient longitudinal timepoints (n=1) with CNA and SNV
data or insufficient tumor purity across all time points to convert the copy number ratios
to integer values. For the remainder of this study, 49 mPC patients have been utilized.

56

Fig. 14: Evaluation of ITH using time points from the mPC cohort at the time of
maximum genomic burden.
a copy number status of the genes in consensus gene list along with the clinical
features and parameters inferred from cfDNA b mutation status of the non-synonymous
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mutations in the consensus gene list along with the clinical features and parameters
inferred from cfDNA c integer copy number heatmap of the 49 time points. Genes are
annotated in red (amplification) and blue (deletion).

Global analysis of the mPC cohort showed that overall CNA burden (CNA count)
is highly heterogeneous in the cohort (range 28-276) (Fig. 14a). The prostate cancer
genes reported previously including AR (n=31), RB1 (n=13), KDM6A (n=11), PTEN
(n=10) and ERG (n=4) had frequent CNAs [126, 147]. Furthermore, our data suggests
that time points with higher computational purity estimates were likely to have a higher
number of CNAs.
Similarly, global analysis of the SNV burden revealed that most patients (n=44)
had less than 100 non-synonymous mutations (Fig. 14b). We found that 2 patients
(PR244 and PR217) had a large number of mutations - 712 and 301 respectively,
consistent with a hypermutant genotype [94, 95]. The prostate cancer genes reported
previously including TP53 (n=15), FOX4DL1 (n=7), AR (n=7) and HMCN1 (n=7) were
highly mutated in our cohort. Our data suggests that time points with higher
computational purity estimates were likely to have a higher number of point mutations.
For the global CNA and SNV analysis, we had picked the representative time
point for every patient as the one which had the maximum tumor mutation burden. Our
data shows that these time points correlate with accelerated progression and a high
volume of disease. Finally, we performed hierarchical clustering on the whole-genome
CNA data (Fig 14c) and found that the patient time points do not show clear
classification into sub-groups. This data suggests that the mPC is highly
heterogeneous with several CNAs unique to the patient. However, regions on the
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chromosomes 8 and 13 are frequently amplified and deleted respectively across the
cohort that include genes such as MYC, BRCA2 and RB1.
Genomic evolutionary classes as a consequence of treatment
We next utilized the CNA and SNV data to investigate whether we could define
clinically meaningful classes of mPC patients. A diploid sample was defined as one that
had less than 30 segments after estimating integer copy number. Based on the trends
in the PSA, genomic patterns observed in the CNA and SNV, we defined 4 classes of
mPC: clonal extinction, clonal progression, intrinsic resistance and partial response.
In the clonal extinction class of patients, we compared the PSA trend,
integer CNA heatmap and cellular prevalence and found that atleast the last 2 time
points had decreasing PSA, diploid CNA (ploidy = 2) and low to undetectable cellular
prevalence at the latter time points (Fig. 15).
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Fig. 15: clonal extinction in 11 mPC patients
a Number of CNAs in 11 mPC patients b Number of non-synonymous mutations in 11
mPC patients c-f examples of 4 clonal extinction patients with decreasing PSA at the
latter time points, diploid CNA profiles at the last 2 time points and
decreasing/undetectable cellular prevalence at the latter time points

In the clonal progression class of patients, we compared the PSA trend, integer
CNA heatmap and cellular prevalence and found that latter time points had increasing
PSA, diploid CNAs at initial time points and cellular prevalence increasing from
low/undetectable at the earlier time points to latter time points (Fig. 16).
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Fig. 16: clonal progression in 9 mPC patients
a Number of CNAs in 9 mPC patients b Number of non-synonymous mutations in 9
mPC patients c-f examples of 4 clonal extinction patients with increasing PSA at the
latter time points, diploid CNA profiles at the initial time points and increasing cellular
prevalence

In the intrinsic resistance class of patients (Fig. 17), the PSA was generally
increasing across all time points. In one patient (Fig. 17f), PR229, although there was a
drop in PSA at the 2nd time point, it was still well above the ‘normal’ PSA value (4
ng/mL). Most of the CNAs and SNVs were consistently detected across all the time
points. An interesting point to note in these patients is that there are several mutations
that seem to decreasing to undetectable levels from high levels or vice-versa,
suggesting that these mutational changes could be due to the selection pressure
induced by the treatment, indicating adaptive or acquired resistance.
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Fig. 17: intrinsic resistance in 8 mPC patients
a Number of CNAs in 8 mPC patients b Number of non-synonymous mutations in 8
mPC patients c-f examples of 4 intrinsic resistance patients with generally increasing
PSA, aneuploid CNA profiles and high cellular prevalence at all time points
In the partial response class of patients (Fig. 18), there was a fluctuating trend in
the PSA. In all the patients, the CNA profiles transition between diploid and aneuploid
while the SNV data fluctuated between high cellular prevalence to low/undetectable
levels.
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Fig. 18: partial response in 21 mPC patients
a Number of CNAs in 21 mPC patients b Number of non-synonymous mutations in 21
mPC patients c-f examples of 4 partial response patients with generally increasing
PSA, aneuploid CNA profiles and high cellular prevalence at all time points

Correlations of cfDNA concentration with genomic features
Next, we investigated the correlations between the cfDNA concentrations and
the genomic features. Samples with a high volume of disease (n=251) had a higher
cfDNA concentration than patients with intermediate (n=95; p=0.047, Wilcoxon rank
sum test) and low volume of disease (n=28; p<0.01, Wilcoxon rank sum test). Samples
with intermediate volume of disease also had a higher cfDNA concentration than
samples with low volume of disease (p<0.01, Wilcoxon rank sum test) (Fig. 13a).
Furthermore, we found that samples with metastatic sites classified as bone (n=193;
p<0.01, Wilcoxon rank sum test), bone+ (n=106; p<0.01, Wilcoxon rank sum test), and
visceral+ (n=61; p<0.01, Wilcoxon rank sum test), had higher cfDNA concentration
samples with lymph node metastasis (n=11). Next, we compared samples based on
their progression rate. We found that samples with accelerated PC growth had higher
cfDNA levels (n = 222) compared to those with protracted kinetics of progression
(n = 152; p <0.01, Wilcoxon rank sum test). Finally, we compared patients based on
their 4 genomic classification. However, none of 4 groups exhibited a significant
difference in terms of the cfDNA concentrations.
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Fig. 19: correlations between cfDNA concentration and clinical features
Distribution of cfDNA concentrations (ng/mL) between samples classified as a) low,
intermediate, and high volume of disease b) bone, bone+, visceral, lymph node, brain
and no sites of metastasis c) accelerated and protracted progressors d) partial
response, clonal extinction, clonal progression and intrinsic resistance. Significance
was calculated using the Wilcoxon rank sum test.

Correlations between cfDNA concentration and longitudinal samples revealed a
few significant features. Time points from patients with high volume of disease (n=251)
had a higher cfDNA concentration compared to the time points from patients with
intermediate (n=95; p = 0.047 Wilcoxon Rank Sum test) and low volume of disease
(n=28; p < 0.05 Wilcoxon Rank Sum test). Similarly, time points from patients with
intermediate volume of disease had a significantly higher cfDNA concentration than the
time points with low volume of disease (p<0.05; Wilcoxon Rank Sum test).
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Next, we investigated the correlation of cfDNA concentration with the metastatic
sites. We excluded categories (no metastasis and brain metastasis) with few time
points from our analysis. We found that time points with bone disease (n=193; p =
0.00063; Wilcoxon Rank Sum test), bone disease + other sites (n=106; p = 0.004;
Wilcoxon Rank Sum test), visceral metastasis (n=61; p = 0.0042; Wilcoxon Rank Sum
test) had significantly higher cfDNA concentration than the time points with lymph node
metastasis (n=11).
Similarly, evaluation of the progression rate revealed that time points with
accelerated progression (n=222; p < 0.01; Wilcoxon Rank Sum test) had a higher
cfDNA concentration that the time points classified as protracted progressors (n=152).
Finally, we tested the correlations between the 4 classes defined in this study and
didn’t find any significant differences in the cfDNA concentration between the 4 classes.

Survival analysis of the patients classified in 4 genomic classes

Fig. 20: Kaplan-Meier survival curve based on the 4 genomic classes
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In Fig. 15-18, we classified the patients into 4 classes based on patterns
observed in the PSA and genomics of the disease. Next, we investigated whether the
patient classes could distinguish the patients based on their overall survival. For this
analysis, we defined the overall survival as the time of initiation of first life prolonging
therapy to date of death or censoring. The Kaplan Meier curves shower clear
separation of the survival curves between clonal extinction and clonal progression
groups. The survival curves of the partial response and intrinsic resistance groups were
between the extinction and progression groups. Overall, the survival analysis had a
significant p-value (p=0.032).
Discussion
In this study, we report the utilization of longitudinal samples to infer the integer
copy number and classify mPC patients into 4 clinically relevant genomic classes:
clonal extinction, clonal progression, intrinsic resistance and partial response.
Our global analysis revealed CNAs in tumor suppressors such as PTEN and
RB1 (often deleted) as well as point mutations in KDM6A and ERG, proteins that
interact with AR gene. In addition to these genes detected in previous mPC studies, a
long list of mutations was also detected in our mPC cohort [136]. This extensive ITH
consistent with previous mPC studies conducted from tumor biopsies [136], suggesting
that our data does indeed capture the extent of ITH in mPC.
Furthermore, the analysis of copy number revealed that a majority of the integer
CN estimates were consistent between time points suggesting that the inference is
likely to be biologically relevant. However, there were occasional discordances that
could be due to sampling difference between time points that causes the CN ratio
normalized by purity and ploidy to round to different CN states. Alternatively, it could be
a true biological variation in the distribution of the sub-clones containing the two CN
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states. In this analysis, we assumed that the ploidy of the tumor does not change
dramatically during treatment. This assumption may not hold true if there are multiple
tumor sub-populations with different overall ploidy’s and the treatment effectively
eliminates one to a few of the sub-populations.
Our longitudinal analysis revealed 4 classes of mPC patients: clonal extinction,
clonal progression, intrinsic resistance and partial response. This approach is in
contrast to studies that have utilized scans to classify the patients [148] or using a small
number of longitudinal tissue biopsies [149]. However, these studies maybe limited by
the number of patients, samples per patient, metastatic sites considered and spatial
heterogeneity [149]. A longitudinal plasma DNA approach could mitigate these
challenges and classify patients in clinically relevant sub-groups by having distinct
survival curves based on the classes, However, some of the patients could be
misclassified due to the timing of the sample collection. This limitation could be
addressed by having a larger number of longitudinal samples in every patient for the
classification problem. Another limitation of the current analysis is that the effect of prior
and current therapies has not been considered.
This study has potential clinical implications. The presence of recurrent diploid
plasma samples may provide an indication of longer survival and better prognosis for
the patient. With the addition of additional mPC patients to each of the classes, the
mutations and CNAs in each of these classes can be analyzed to determine if there are
pathways that are consistently disrupted in each of them. Additionally, a larger number
of baseline samples in each of these classes may help in building a model that can
assist the oncologist in understand the patient prognosis better. The non-invasive
longitudinal sampling classification approach may be useful in many cancers where
sufficient ctDNA is detected in the blood.
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Methods
The previous chapter was a technical study to deconvolute the tumor
architecture from longitudinal plasma samples. The methods reused from the previous
chapter have been included as sub-headings (in italics) in this section. The text can be
read from the chapter 3 methods section. The text in this methods section contains
updates from chapter 3 as well as new methods.
Patient clinical data and sample information
All patients in this study were treated for prostate cancer at the University of
Texas MD Anderson Cancer Center (Houston, TX) and provided informed consent per
an Institutional Review Board-approved prospective protocol. Two patient cohorts were
included: (i) newly diagnosed metastatic and hormone-naïve (CSPC) and (ii) CRPC. All
the blood plasma samples were collected before initiation of systemic treatment (pretreatment), while progressing on therapy by PSA or radiologic criteria (post-treatment),
or while on systemic treatment as indicated (on-treatment). Patients were prospectively
followed from the time of inclusion until the last visit or death. The clinical classification
of the patients can be reviewed in the previous chapter.
Isolation of plasma DNA from blood plasma and quality control
Plasma DNA library construction and exome sequencing
The exome libraries were captured using either the SeqCap EZ Exome V2 kit
following the manufacturer’s instructions (Nimblegen-Roche Cat. no. 05860482001) or
the SeqCap EZ Exome V3 kit (Nimblegen-Roche Cat. no 06465692001). The final
exome libraries were sequenced at 76 or 100 paired-end reads on the Illumina
HiSeq4000 system.
Analysis of genomic copy number data using circular binary segmentation (CBS) from
plasma DNA
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Estimating ploidy and purity from low-pass whole genome sequencing data
Ploidy and purity for the longitudinal plasma samples were inferred using
ichorCNA [47]. The read count file (WIG file) was generated using the readCounter
function from the HMMcopy package. The readCounter function used a 500kb window
size, quality score of 20, all 24 chromosomes and the bam file as input. For estimating
the purity and ploidy, the WIG file from readCounter was used along with sample id,
initial tumor ploidy initialization ranging from 2-4, normal contamination initialization
from 0 to 1.0 (at increments of 0.1), maximum copy number as 10, chromosomes,
training chromosomes and normalize chromosomes set to chr1-23. All other
parameters used were the default values while the default wig files were replaced with
the ones appropriate for 500 kb instead of 1000 kb. For every bam file (time point), the
output file contains a number of estimated copy number profiles ranked by likelihood
score and adjusted for purity and ploidy.
Estimating integer copy number from low-pass whole genome sequencing data
The assumption made for the copy number estimation is that the ploidy between
longitudinal time points across a patient will be roughly similar. Using this assumption,
a ploidy solution(s) was picked if it was reported as one of the solutions by ichorCNA
across all time aneuploid time points. For a given ploidy solution, purity reported by
ichorCNA was considered as the true purity. When a sample had low tumor purity, it
was considered as a normal sample (purity = 0, ploidy = 2).
The normalized segmented read ratios obtained from CBS pipeline described in the
previous chapter was corrected to integer copy number using the formula:

Integer CN for chr 1 − 22 =

CNA ratio – (1-purity)
x ploidy
mean(new CNA ratio)
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The purity correction factor for chr X and Y was ichor estimated purity/2 because
prostate cancer patients (males) have half the number of sex-chromosomes compared
to autosomes. All the normalized values were rounded to the nearest integer (copy
number state) and the solution was accepted if all the aneuploid samples had a
minimum integer copy number state as 0 and low variance in the corrected normalized
ratios. If there were multiple ploidy solutions from ichorCNA that fit these criteria, the
minimum ploidy was considered as the optimal solution.
Detection of mutations in plasma exome sequencing data
The plasma DNA data from each patient was aligned to the human genome
reference assembly (hg19) using Bowtie2 (2.1.0) [108] and converted into a binary
format (BAM) with Samtools [109]. The SAM file was sorted using samtools, and PCR
duplicates were marked using Picard tools [114]. Genome Analysis Toolkit [110]
(GATK)’s BaseRecalibrator were used to obtain BAM files that have been recalibrated
for base quality scores. Somatic variants were identified using the plasma and matched
PBMC samples using GATK’s MuTect2 [115] to generate a variant call format (VCF)
file. As the longitudinal samples were sequenced with either the SeqCapV2 or the
SeqCapV3 exome capture, we restricted the variant calling to the intersection of the
two captures, which is equivalent to SeqCap V2 capture regions. The filtering
functionality of the MuTect2 VCF file was enabled using GATK’s FilterMutectCalls for
the variants detected on the SeqCap V2 exome panel and the somatic variants
classified as “PASS” (high confidence) were retained. The filtered somatic variants
were split into single nucleotide variants (SNVs) and indels using GATK’s
SelectVariants function. The chromosome number and position of the variants were
extracted, and samtools was used to obtain the read counts across all the variant sites.
Variants with less than 0.05 variant allele frequency in the plasma sample were
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removed from analysis. Additionally, variants were removed from analysis if they had
more than 2 variant reads and more than 0.1 variant allele frequency in the PBMC
samples. The resulting data was annotated using ANNOVAR [116] by integrating
multiple databases, including dbSNP, COSMIC [117], and the Cancer Gene Census
[118]. To identify mutations in genes of interest, an exon coordinate file was intersected
with BedTools [119]. The functional significance of each SNV was predicted using SIFT
[120] and POLYPHEN [121]. Mutations with < 0.05 SIFT scores and > 0.85 POLYPHEN
scores were considered significant for impacting gene function.
Estimating clonal frequencies from mutation data
Non-synonymous and synonymous somatic mutations were identified in the
plasma samples for mPC patients with 2 to 6 longitudinal samples. The variant allele
frequencies from each point mutation were normalized with both exome-derived copy
number profiles and estimated tumor purities using PyClone2 (v0.12.9) [25]. The copy
number and purity-adjusted clonal frequencies were then used as input for CITUP [29]
for the joint calculation and estimation of clonal subpopulations using the optimal trees
across the longitudinal timepoints from same patient. Finally, the clonal lineages were
plotted with “timescape” [124] using the CITUP tree structures and the clonal
frequencies across the longitudinal timepoints for individual PC patients.
Survival analysis by plasma DNA concentration
We utilized survival data from 49 mPC patients with plasma samples for survival
analysis. The samples were categorized into 4 categories based on genomic patterns:
clonal progression, clonal extinction, intrinisic resistance and partial response groups.
The overall survial and the group information were used for survival analysis using the
Kaplan-Meier estimator using the “survminer” library in R (3.5.0). The p value of the
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log-rank test was calculated, and the two groups were considered significantly different
if the p value was p ≤ 0.05.
4. Discussion
The work done for this dissertation has been reported in chapters 3 and 4. In
chapter 3, the development of PEGASUS has been reported. This method is a whole
genome cfDNA sequencing approach that utilizes archival plasma samples and does
not require prior knowledge of the genomic aberrations in the tumor. This approach can
provide a large number of genomic markers that are necessary to infer the tumor’s
subclonal architecture. Chapter 4 is an illustration of how PEGASUS approach can be
utilized in a larger cohort of mPC patients, to understand the heterogeneity of the
disease, classify the patients based on genomic patterns and understand the survival
differences between the patient classes.
Although scientists have utilized innovate methods to profile bulk tumor tissues
or single cells to study cancer, challenges such as a limited number of longitudinal
tumor samples, accessibility to metastatic samples and spatial bias between samples
have remained as major challenges. Prostate cancer patients may have multiple
metastatic lesions but only one of those sites can usually be sampled by the clinician
due to feasibility and patient safety concerns. These limitations have been particularly
pressing in cancers such as mPC where access to metastatic tumor tissues such as
bone has been very challenging for longitudinal profiling. These technical and logistical
difficulties have contributed to a gap in knowledge limiting the understanding of mPC.
This study provides an illustration of how these limitations could be mitigated by using
blood samples collected routinely during mPC treatment. In addition to the mPC
challenges, most cfDNA approaches have been limited to clinical genotyping of single
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targeted mutations or gene panels and have not been amenable to genome-wide
discovery research.
To address these limitations, this dissertation reports the development of a
whole-genome plasma DNA sequencing approach called PEGASUS to profile both
copy number and point mutations from archival plasma samples. Comparisons
between CNA and SNV data revealed that cfDNA detects genomic aberrations that
may not be detected by the tumor tissue, consistent with existing body of literature [56,
150]. These data suggest that longitudinal profiling of plasma DNA may reduce the bias
due to intra tumor heterogeneity [133], multiple prostate cancer foci, spatial bias and
several metastatic sites. Another challenge that has been addressed by this study is
the delineation of mPC sub-clones longitudinally during therapy. Our data from 9 mPC
patients showed that a rare subpopulation detected at the earlier time points expanded
to high frequencies at the later time points suggesting that these clones may contain
mutations contributing to the fitness advantage of the mPC.
This PEGASUS study is limited by the number of patients and the diverse nature
of therapies at the sample collection time points making the inferences between
patients challenging. Another limitation of this PEGASUS approach is that the
performance is limited when the tumor fraction in the cfDNA is low. Therefore, in a
prostate cancer setting, PEGASUS has the ability to detect sufficient ctDNA to call
CNAs and SNVs efficiently in advanced mPC patients over those who have early stage
disease that release very little tumor DNA into the blood. In such situations, it is difficult
to differentiate tumor signal from technical noise. When any low purity sample is
considered, the integer copy number inference approach becomes ineffective. This is
because the tumor signal and the noise have a similar range of segmentation CN ratios
and multiplying the data by ploidy amplifies the signal and noise by similar proportions.
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In contrast to a bulk sequencing approach such as cfDNA, another non-invasive
marker that can trace tumor evolution are the circulating tumor cells (CTCs). Since
these are shed into blood stream by the tumor, these CTCs could, in theory, capture all
the heterogeneity of the tumor cells, specifically those that have metastatic potential.
Single cell sequencing methods have been utilized to show that sequencing CTCs is
feasible and can be used to make inferences about the tumor [97]. Individual and
pooled CTCs have been utilized to infer tumor evolution [151]. Several other studies
have shown that CTCs in combination with the tissue can be utilized to understand the
evolution of metastasis [152]. Recent studies have also shown heterogeneity between
CTCs clones and emergence of new clones with resistance associated genomic
aberrations during therapy [153]. However, the major issue with CTCs is that it is not
yet clear how much of the heterogeneity is represented by them and how many CTCs
would be required to capture the entire sub-clonal substructure [154]. Currently, most of
the CTC enrichment methods are either a labor-intensive process that involves manual
intervention, thereby, limiting the number of tumor cells being picked. Alternatively, they
utilize cellular markers or properties with the assistance of micro fluidic devices to
enrich for CTCs at the cost of specificity and sensitivity [155]. In spite of these
limitations, CTCs remain a promising area of research and can improve our
evolutionary understanding of the tumors once the isolation technologies become
efficient.
Another challenge unique to mPC is that it is difficult, often impossible to
quantify response and resistance using approaches such as RECIST criteria due to the
extensive bone metastasis. The patient classification is generally based on clinical
features factors such as PSA, metastasis and disease state in addition to evaluation of
routine scans. Therefore, chapter 4 in this dissertation describes how PEGASUS can
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be applied to classify patients into 4 clinically meaningful sub-groups. In this study, our
single time point analysis of the integer copy number and point mutations illustrate the
extent of ITH in mPC. The point mutation count shows that the patients have a large
number of mutations in addition to the consensus gene list which is in line with existing
studies, reflecting ITH and a long list of driver mutations in PC [136]. Additionally, the
longitudinal CNA and mutation data from these mPC patients have been used to
classify them into 4 genomic classes: clonal progression, clonal extinction, intrinsic
resistance and partial response. These classes reflect when the tumor fraction at the
time points drop below our detection threshold.
In the clonal progression group, prior treatment had eliminated the presence of
ctDNA in the blood in the earlier time points reflected by diploid cfDNA CNA profiles but
aneuploid CNA profiles were observed at the subsequent time points. These patients
have an increasing PSA and MAF at the latter time points. In contrast to the clonal
progression patients, clonal extinction patients transition from aneuploid time
points/high tumor fraction at earlier time points to diploid/low tumor fraction at the latter
time points. This is consistent with a drop in PSA and MAF at the latter time points. The
intrinsic resistance class of patients consistently showed aneuploid CNA profiles at all
the sequenced time points. The PSA for these patients were generally increasing while
a majority of the point mutations were observed at all the time points. The partial
response class of patients showed fluctuations between diploid and aneuploid CNA
profiles, PSA and MAF. In contrast to the two classes identified in chapter 3, four
classes were identified in Chapter 4 study primarily due to the availability of a larger
number of time points. Survival analysis of the 4 genomic classes of mPC suggests
that order of survival of the groups is clonal progression, intrinsic resistance, partial
response and clonal extinction, which is in line with the clinical expectation of survival
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order. This data suggests that longitudinal plasma sequencing data can be utilized to
classify patients into clinically meaningful classes. This classification maybe more
robust compared to classification using PSA because the results are less likely to be
affected by confounders such as urinary track infection, injury, and age.
Although we report 4 clinically relevant classes of mPC patients, the study has a
few limitations. Some of the patients included in this study have a limited number of
longitudinal samples and could cause some of the patients to be misclassified. For
example, let us consider a situation where a patient had a response during a treatment,
but pre and post treatment samples were collected. Assuming the cfDNA has a diploidlike profile during treatment, the patient is likely to get classified as an intrinsically
resistant patient instead of a partial responder if the during treatment sample was not
collected. With the growing number of therapies being utilized for the mPC treatment,
the heterogeneity in prior therapies remains a confounding factor in assessing the
genomics of the disease.
Future Directions
Although this dissertation has addressed some challenges to improve the
understanding of evolution and resistance in prostate cancer, several issues remain to
be addressed. The PEGASUS approach has its limitations when the tumor fraction is
low, which is the likely situation in patients when they are diagnosed at the early stages
of cancer. At the earlier stages of cancer, we speculate that there is ctDNA in the blood
but it is below our detection efficiency. Therefore, methods such as molecular
barcoding could be incorporated into the PEGASUS approach to improve the detection
efficiency of ctDNA [156]. These methods can reduce the false positive variants and
assist in better detection of rare variants. Incorporating molecular barcoding into our
PEGASUS approach may improve our variant detection at the response time points
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where the tumor fraction in the blood remains low. This approach may also be
applicable to other situations that lead to low tumor fraction such as studies to evaluate
early stages of cancers and cancer recurrence. Furthermore, a highly sensitive
detection of mutations can help distinguish the acquired from adaptive mode of
resistance.
A second challenge has been the heterogeneous number of time points. A larger
study containing CNA and SNV data from patients where a large number of time points
were collected from diagnosis to the late stages of the disease would improve the
accuracy of the patient classification. A large number of time points can also improve
the classification by accounting for the various therapies received by the patient. This
large dataset may be useful in addressing some of the existing challenges in mPC and
assist clinicians in better understand the patient prognosis, choose better treatments
and time the administration of the treatment. For instance, baseline time point analysis
of the 4 evolutionary classes with sufficient number of patients may provide insights
into features that are predictive of the long-term trajectory of mPC. Similarly, clinically
meaningful subsets of the longitudinal data using variables such as treatment may be
useful to identify gene signatures that could predict the response to therapies.
In this dissertation, we investigated the utility of longitudinal samples in defining
clinically meaningful patient classes. In additional to the longitudinal data, a
classification based on tumor mutation burden, copy number burden and other genomic
markers should be further evaluated. Since the data in this study is utilizing plasma
instead of invasive biopsies, these analyses could provide better patient classification
as they are less likely to be affected by foci, spatial and metastatic lesion differences.
Preliminary clonal dynamics analysis of the mPC patients (Fig. 17-18) reveals
that there may be mutations that positive or negative selection due to the effect of
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therapy. However, chapter 4 in this dissertation has not accounted for the effect of
therapy in mutation changes. The mutations that belong to resistant or sensitive clones
will need to be further validated androgen dependent or androgen independent cell
lines to understand if they truly play a role in the sensitivity or resistance to the
particular therapy. Furthermore, these mutations need to be evaluated further to
understand if the same genes or pathways are disrupted between multiple patients,
within the same therapy and/or between patients with the same global evolutionary
class. In the event that similar mutations or pathways are detected across patients
during therapy, we could develop a gene panel to screen patients for these specific
abnormalities which may assist the clinicians in their treatment decisions.
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